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ABSTRACT OF THE DISSERTATION  
SELECTIVE AND SPECIFIC ACTIVATION OF RAB5 DURING ENDOCYTOSIS OF 
RECEPTOR TYROSINE KINASES 
by 
Ivan Jozic 
Florida Inernational University, 2013 
Miami, Florida 
Professor M. Alejandro Barbieri, Major Professor 
The Rab family of proteins are low molecular weight GTPases that have the ability to 
switch between GTP- (active) and GDP- (inactive) bound form, and in that sense act as 
molecular switches. Through distinct localization on various vesicles and organelles and 
by cycling through GTP/GDP bound forms, Rabs are able to recruit and activate 
numerous effector proteins, both spatially and temporally, and hence behave as key 
regulators of trafficking in both endocytic and biosynhtetic pathways. The Rab5 protein 
has been shown to regulate transport from plasma membrane to the early endosome as 
well as activate signaling pathways from the early endosome.  This dissertation focused 
on understanding Rab5 activation via endocytosis of receptor tyrosine kinases (RTKs). 
First, tyrosine kinase activity of RTKs was linked to endosome fusion by demonstrating 
that tyrosine kinase inhibitors block endosome fusion and activation of Rab5, and a 
constitutively active form of Rab5 is able to rescue endosome fusion. However, 
depending on how much ligand is available at the cell surface, the receptor-ligand 
complexes can be internalized via a number of distinct pathways. Similarly, Rab5 was 
activated in a ligand-dependent concentration dependent manner via clathrin- and 
vii 
 
caveolin-mediated pathways, as well as a pathway independent of both. However, 
overexpression Rabex-5, a nucleotide exchange factor for Rab5, is able to rescue 
activation even when all of the pathways of EGF-receptor internalization were blocked. 
Next, the three naturally occurring splice variants of Rabex-5 selectively activated Rab5. 
Lastly, Rabex-5 inhibits differentiation of 3T3-L1 and PC12 cells through 1) degradation 
of signaling endosome via Rab5-dependent fusion with the early endosome, 2) and 
inhibition of signaling cascade via ubiquitination of Ras through the ZnF domain at the 
N-terminus of Rabex-5.  
In conclusion, these data shed light on complexity of the endosomal trafficking 
system where tyrosine kinase activity of the receptor is able to affect endosome fusion; 
how different endocytic pathways affect activation of one of the key regulators of early 
endocytic events; and how selective activation of Rab5 via Rabex-5 can control 
adipogenesis and neurogenesis. 
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INTRODUCTION 
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1.1 Different routes of endocytosis 
Endocytosis is a process by which cells internalize extracellular material (in the form 
of nutrients, hormones, pathogens, or any other extracellular matter) that is essential for 
normal cell function but which is either too large (or too polar) to pass across the plasma 
membrane. Endocytosis of molecules has a multitude of functions in the cell, from 
cellular growth, division, differentiation and signal transduction, among others 
[McMahon & Boucrot, 2011]. The key routes of entry into the cell are through Clathrin- 
and Caveolin-mediated or carrier independent endocytosis (which could be either 
dependent or not on Dynamin), along with Macropinocytic and Phagocytic pathways 
(Figure 1).  
Clathrin Mediated Endocytosis (CME) is the classical endocytic pathway which 
involves recruitment of receptor(s) into clathrin coated pits (CCPs), invagination of the 
plasma membrane, vesicle scission, shedding of the vesicle coat, fusion with the early 
endosome and sorting at the Multi-Vesicular Body (MVB) either for recycling or 
degradation in the lysosomes [Sorkin, 2004].  The membrane coat is made up of clathrin, 
various adaptor proteins and phosphatidylinositol (4,5) bisphosphate or PI(4,5)P2. The 
pathway is mainly regulated by Dynamin and Rab proteins, which respectively are 
responsible for the scission of the CCP and activation of their respective effectors in turn 
regulating vesicle budding, motility and fusion [Zerial & McBride, 2001]. CME is used 
by all known eurkaryotic cells and is very versatile because many different cargoes can 
be packaged therein using a range of accessory adaptor proteins. Although clathrin-
coated vesicles can also be formed from other membranous compartments and used for 
various cellular processes (such as endosomal sorting complex required for transport, 
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ESCRT-dependent sorting at endosomes [Raiborg et al., 2001], protein secretion from the 
trans-Golgi network [Deborde et al., 2008] and mitosis [Royle et al., 2005]), the term 
CME is used to refer only to the intake through vesicles formed from the plasma 
membrane [McMahon & Boucrot, 2011]. 
Clathrin has been shown by numerous studies to play a key role in the endosomal 
sorting process [van Dam & Stoorvogel, 2002; Raiborg et al., 2002]. Depletion of 
clathrin from cells leads to an ablation of CCP formation and subsequent endocytosis of 
the receptor. Adaptor proteins, such as adaptor protein 2 (AP2), have also been shown to 
play a key role in CME as depletion of AP2 has been shown to inhibit formation of the 
clathrin coat [Sorkin, 2004; Maldonado-Baez & Wendland, 2006; Motley et al., 2003; 
Bourcot et al., 2010]. By binding to the head groups PI(4,5)P2 and PI4P 
(Phosphatidylinositol 4-Phosphate), AP2 acts as a link between clathrin and the 
underlying membrane and hence its depletion, though may not inhibit CME completely, 
will lead to a decrease in CME [Bourcot et al., 2010]. Alternative adaptor proteins (such 
as Epsin, β-arrestin, AP180/CALM (adaptor protein 180/Clathrin assembly lymphoid 
myeloid leukemia protein), Hip1 (Huntingtin Interacting protein 1), Dab2 (disabled 
adaptor protein 2), ARH (autosomal recessive hypercholesterolemia)) are also known to 
exist and play a key role in CME.  Inhibition of AP2 only knocks down CME dependent 
EGFR (Epidermal growth factor receptor) uptake by about 50 percent, which makes 
sense because the aforementioned adaptor proteins themselves can bind to clathrin, cargo 
as well as phosphoinositides. In addition, during the depletion of AP2 there would be less 
clathrin and subsequently less CCPs on the plasma membrane, hence it is logical that 
CME should decrease but should not be completely inhibited [Huang et al., 2004; 
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Lakadamyali et al., 2006; Sigisimund et al., 2008]. Once dynamin pinches off the CCP 
from the plasma membrane, auxilin and hsc70 work in concert to release the clathrin coat 
from the excised vesicle [Doherty & McMahon, 2009]. 
Although CME is the most widely studied and best understood model of endocytosis, 
cargo can be endocytosed via pathways independent of clathrin. Moreover these 
pathways function in a cholesterol-dependent manner, in contrast to CME which is cargo 
driven. One of the plausible reasons for employing a variety of different forms of 
endocytosis is to perhaps deliver cargo to distinct intracellular destinations by creating 
endosomal compartments with specific membrane protein composition, which would 
therefore direct the variety of distinct intracellular events.  
During Caveolin Mediated Endocytosis (CavME) (Figure 1), the coat is composed by 
oligomerization of caveolin that in turn forms lipid rafts which are budding inward and 
directed toward caveosomes that can be directed to early endosomes and hence converge 
with the aforementioned classical CME pathway in a process that is regulated by Rab5 
[Parton & Simons, 2007; Pelkmans et al., 2004]. The CavME pathway is activated 
through PKC and SRC (sarcoma) family kinases. Caveolae are the 80nm invaginations 
(analogous to CCPs from CME) through which CavME occurs with the help of dynamin 
as the GTPase required for the vesicle scission from the cell membrane. CavME have 
been observed in smooth muscle, pneumocytes, fibroblasts, adipocytes and endothelial 
cells [Parton & Simons, 2007].  
Cells can also internalize cargo in a clathrin- and caveolin-independent manner 
(Figure 1). The first is through a pathway regulated by flotillin, which is homologous to 
caveolin, but whose cargo has been found in plasma membrane domains distinct from 
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caveolae. Epidermal Growth Factor (EGF) also stimulates the flotillin pathway, but 
interestingly it has not been shown to associate with EGFR. Cell surface proteoglycans 
are internalized in a CavME and CME independent manner with vesicle scission being 
controlled by dynamins [Paynet et al., 2007]. On the other hand, 
Glycosylphosphatidylinositol-anchored proteins are taken up by pathways independent of 
clathrin and caveolin, known as CLIC/GEEC (Clathrin and Caveolin Independent 
Carriers/GPI-anchored protein enriched Early Endocytic Compartment) pathways, and 
are regulated by CDC42 (Cell Division Control protein 42 homolog) and Arf1 (ADP 
ribosylation factor 1) through tubular plasma invaginations [Kumai & Mayor, 2008; 
Doherty & Lundmark, 2009]. The aforementioned pathways, however, do not always 
require dynamin to pinch off from the plasma membrane [Lamaze et al, 2001] and have 
been shown to internalize SV40 virions, CTxB (Cholera Toxin subunit B), other 
sphingolipids, IL2 (Interleukin-2) receptors, AMF (autocrine motility factor), endothelin, 
growth hormones as well as other molecules [Kirkham & Patron, 2005]. Interestingly 
vesicles from this pathway can bypass the canonical Rab5 endosomes. 
Molecules can also be macropinocytosed into the cell via macropinosomes, which are 
membrane protrusions that can fuse with themselves or back with the plasma membrane 
and create endocytic vesicles that are capable of internalizing extracellular fluid (along 
with other cargo) that is greater than 1µm in diameter and independent of clathrin but 
dependent on cholesterol (Figure 1). These are regulated by Rac1, actin, Arf6 and the 
WAVE (WASP family Verprolin-homologus protein) complex and initiated by growth 
factors, for which Rab5 is a crucial controller of [Lanzetti et al., 2005]. Numerous 
proteins such as PI3K, Ras and Src have all been shown to stimulate macropinocytosis 
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[Veithen et al., 1996]. It has also been shown that in response to high concentration of 
ligand (EGF, PDGF (platelet derived growth factor) or HGF (hepatocyte growth factor)) 
certain receptor tyrosine kinases (EGFR, PDGFR) move along the dorsal surface of 
membranes on structures that have been termed circular dorsal ruffles (CDRs) whose 
internalization appears to be dependent on cortactin and dynamin. What is interesting is 
that the receptors become internalized very rapidly through tubular rather than circular 
structures that are independent of clathrin or caveolin [Li et al., 1997; Krueger et al., 
2003; Doherty & McMahon, 2009]. The significance of the aformenetioned for the cell is 
probably to desensitize cells to large concentrations of ligand.  
1.2 Abnormalities associated with derailed endocytosis 
Aberrant endocytosis can very easily lead to pathogenesis associated with 
neurodegenerative diseases, cancer metastasis, kidney disease, as well as insulin 
resistance and other metabolic disorders.  For example, Cdc42-gtp targets junctional 
proteins to lysosomes, while cdc42-gdp targets them to recycling endosomes that contain 
Rab13. Furthermore, overexpression of Cdc42 has been shown to be associated with 
advancement of testicular cancer [Kamai et al., 2004]. On the other hand, EGF is able to 
phosphorylate PAR3 (Partitioning defective proteins) and establish tight junction 
polarity, while HER2 (Human Epidermal growth factor Receptor or the oncogenic 
receptor ERBB2 (Erythroblastic leukemia viral oncogene homolog 2)) binds to PAR6, 
recruits αPKC (Protein Kinase C) and thereby disrupts polarity [Aranda et al., 2006; 
Wang et al., 2006]. An E3 ubiquitin ligase, von Hippel-lindau protein on the other hand, 
targets αPKC for degradation and therefore inhibits the polarity disrupting effects of 
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HER2 [Okuda et al., 2001]. E-cadherin can be internalized by CME, as well as CavME 
through EGF stimulated macropinocytosis [Bryant et al., 2007]. If E-cadherin can not 
trap B-catenin at the cytoplasm, the latter translocates to the nucleus and activates the wnt 
pathway, which is known to control polarity and cell migration [Nelson & Nusse, 2004].  
Rab4-GTP interacts within trans-Golgi network via N-Myc Down Regulated Gene 1, 
also known as NDRG1 (a suppressor of prostate and breast metastasis) to recycle E-
cadherin, while Rab11 (when residing in the recycling endosomes) regulates the 
trafficking of E-Cadherin to basolateral surface from the Golgi network along with 
activating Rap1 [Balzac et al., 2005; Kachhap et al., 2007]. Because endosomal 
acidification is required for endocytosis of low molecular weight proteins in the proximal 
convoluted tube, aberrant endocytosis of the machinery responsible for acidification of 
endosomes has been shown to the be one of the main causes of renal Fanconi syndrome 
and Dent’s disease [Devuyst, 2010]. 
Regulation of endocytosis also plays a role in pathogenesis of type II diabetes since 
GLUT4 (Glucose Transporter Type 4, which is the principal carrier responsible for 
glucose transport) in the cell membrane is controlled by both CME as well as caveolin 
independent (but cholesterol and dynamin dependent) endocytosis [Antonescu et al., 
2008], and hence mis-regulation of either pathway could lead to insulin resistance.  
Atherosclerosis is a condition in which there is an accumulation of cholesterol 
without subsequent clearing that subsequently leads to the thickening of the arterial wall. 
However, if an inhibitor of dynamin (a GTPase involved in the scission of budding 
vesicles) is employed, reduction in atherosclerosis is achieved by enhancing TGF-β and 
thereby offsetting the repressed awareness caused by hypercholesterolemia [Chen et al., 
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2009] supporting the evidence that receptor mediated endocytosis is involved in 
pathogenesis of atherosclerosis.  
It has also been shown that endocytosis is involved in pathogenesis of muscular 
dystrophy as caveolin specifically inhibits dysferin endocytosis thereby causing its 
retention at the cell surface (since mutations in the caveolin and dysferin are associated 
with limb girdle muscular dystrophy type 2b) [Hernandez-Deviez et al., 2008]. 
Lysosomal storage disease (LSD) is a group of genetic diseases characterized by the 
presence of enlarged late endosomes and lysosomes in neuronal cells potentially caused 
by either faulty late endosomal tubular trafficking, reduced lysosome-mediated retrograde 
transport and exocytosis or abnormal endocytic lysosomal sorting [Zhang, 2008].  
Alzheimer’s disease is another neurodegenerative disease in which aberrant endocytosis 
of Amyloid Precursor Protein (APP) and subsequent accumulation of the truncated and 
ultimately toxic form Aβ42 leads to buildup of β-amyloid plaques and pathogenesis of 
the disease [Zhang, 2008]. 
Another neurodegenerative disorder associated with abnormal endocytosis is 
amytrophic lateral sclerosis (ALS). The ALS2 protein is one of the GEFs associated with 
activation of Rab5 (via the VPS9 domain) as well as Rac1. Recently, it has been shown 
that the loss of functional VPS9 domain of the ALS2 protein is enough to stimulate ALS 
[Otomo et al., 2003].  
Menkes Disease is associated with an abnormally high absorption of copper in 
kidneys and the small intestine which then leads to copper deficiency in other tissues 
such as the brain. Although copper is an essential trace element, high concentrations of it 
are toxic, therefore it needs to be under strict homeostatic control, which is done through 
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both clathrin dependent and indpenedent endocytosis of MNK (Menkes disease protein) 
copper-transporting P-type ATPase [Lane et al., 2004].  
Hence, it is evident that a thorough understanding of the mechanisms underlying the 
various types of endocytosis are essential for elucidating the pathogenesis of numerous 
debilitating conditions ranging from cancer to several neurodegenerative and metabolic 
disorders. 
1.3 Endocytosis of Epidermal Growth Factor Receptor (EGFR) 
Epidermal Growth Factor Receptor (EGFR or ERBB1) is a member of the Receptor 
Tyrosine Kinase (RTK) family of receptors which also include the ERBB2/HER2, 
ERBB3 and ERBB4 receptors. The structure of these receptors is such that they contain 
an extracellular ligand-binding domain composed of two cysteine rich regions (for 
ligands ranging from EGF, TGFα (Transforming Growth Factor), amphiregulin, HB-EGF 
(Heparin-binding EGF-like growth factor) and a number of virally-encoded factors), an 
alpha helical transmembrane domain, leading to an intracellular domain. The intracellular 
domain is of interest because it possesses tyrosine kinase activity that is comprised of a 
PKC/MAPK attenuation site followed by an SH1 (Src homology 1), and a C terminal tail 
which adaptor proteins which contain SH2 (Src Homology 2) and PTB (Phosphotyrosine-
binding) domains can interact with [Wells, 1999; Woodworth et al., 2005]. Upon binding 
of a ligand, EGFR homodimerization or heterodimerization (with other members of the 
EGFR family) occurs, leading to the activation of the tyrosine kinase domain and 
autophosphorylation of tyrosine residues which activate MAPK, PKC and PI3K signaling 
pathways via various adaptor proteins [Wells, 1999]. It is known that if EGF stimulation 
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is greater than 10ng/ml, majority of the EGFR is destined for degradation via clathrin 
independent pathway(s), whereas if stimulation is less than 2ng/ml, majority of the 
receptor is destined to be recycled to the cell surface via CME (Figure 1) [Sigisimund et 
al., 2005; Sigisimund et al., 2008;]. However, internalized receptor through either 
pathway is destined for early endosome sorting [Sigisimund et al., 2008]. In the CME 
pathway, upon binding of EGF, receptor dimerizes over the clathrin coated pit and gets 
endocytosed. What follows is multiubiquitination of EGFR and subsequent degradation 
of both the receptor and the ligand at Multi-Vesicular Body [Levkowitz et al., 1999]. 
Interestingly, if TGFα or HB-EGF binds to the EGFR, what results is a 
hypoubiquitination of the EGFR (because of their instability in acidic compartments), 
leading to recycling of the receptor to the cell surface and continuous signaling, which is 
a hallmark observed in lung, ovarian, colon and prostate cancer malignancies [Ebner & 
Derynck, 1991; Nicholson et al., 2001].  
1.4 Disorders arising from misregulation of EGFR 
EGFR is also involved in numerous signaling cascades in which it is known to 
activate the Mitogen-Activated Protein Kinase (MAPK), PLCγ, PLD, PI3K-Akt 
pathways, as well as activation of transcription signaling pathways [Kumar et al., 2008]. 
Therefore, aberrant activation or trafficking of the receptor can lead to various oncogenic 
and malignant diseases, especially Non-Small-Cell Lung Cancer (NSCLC) which is the 
leading cause of cancer death in North America [Jemal et al., 2005].  However, inhibition 
of the EGFR using either siRNA or synthetic inhibitors (such as PD153035) and 
examination of affected genes (using a microarray) have shown that inactivating EGFR 
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also has an effect on gene expression of various cellular processes ranging from 
proinfalmatory responses, genes that promote cell attachment, apoptosis as well as those 
which inhibit cell cycle progression [Woodworth et al., 2005]. EGFR has also been 
implicated to be involved in PKD (Polycystic Kidney Disease) where there is an 
overexpression and mislocalization of EGFR that can be reversed with use of 
pharmacological or genetic inhibitors of EGFR tyrosine kinase activity [Torres et al., 
2003]. Lastly, it has been shown that constitutive activation of the EGFR can lead to 
cirrhotic liver disease and can ultimately lead to Hepato Cellular Carcinoma (HCC) 
[Komuves et al., 2000; Buckley et al., 2008].  
1.5 Role of small GTPases in intracellular trafficking  
The Rab family of proteins is a subset of a superfamily of Ras proteins, which are low 
molecular weight GTPases (20-30 kD) that have the ability to switch between GTP 
(active-membrane bound) and GDP (inactive-cytosolic) bound form, and in that sense act 
as molecular switches [Li & Stahl, 1993; Barbieri et al., 1994;, Li et al., 1994; Barbieri et 
al., 1996].  Including various isoforms, currently the family comprises of over 60 
members [Stenmark & Olkonen, 2001; Baskys et al., 2007]. All Rab proteins have a 
GTPase domain and are isoprenylated at their C terminus for integrating into different 
membranes. Through distinct localization on various vesicles, and organelles and by 
cycling through GTP/GDP bound forms, Rabs are able to recruit and activate various 
effector proteins, both spatially and temporally, and hence behave as key regulators of 
trafficking processes in both endocytic and biosynhtetic pathways (vesicle budding, cargo 
sorting, tethering, as well as docking and fusion of vesicles with acceptor membranes). 
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The cycling between the active (GTP-bound) and inactive (GDP-bound) forms depends 
on auxiliary elements that control association with membrane(s), binding of nucleotide(s) 
and GTP hydrolysis [Delprato et al., 2004].  
1.5.1 Rab5 
The Rab5 protein is ubiquitously expressed and has been shown to regulate 
transport from plasma membrane to the early endosome. It has also been shown that the 
protein is required for homotypic early endosome fusion and its overexpression has been 
shown to increase the rate of endocytosis [Li & Stahl, 1993; Barbieri et al., 1994;, Li et 
al., 1994; Barbieri et al., 1996; Chiariello et al., 1999]. It has also been shown to be 
involved in regulating generation of phophotidylinositol-3-phosphate lipid which is 
enriched in the early endosome membrane [Murray et al., 2002] and the motility of early 
endosomes on actin and microtubule filaments [Pal et al., 2006], as well as activating 
signaling pathways from the early endosome [Schenck et al., 2008]. There are three 
isoforms of Rab5, those being Rab5a, Rab5b and Rab5c (Figure 2), which show about 
80% sequence homology and all of which have been shown to be involved in regulating 
dynamics of early endosome fusion [Bucci et al., 2010]. Hence, the presence of Rab5 
isoforms may reflect an evolutionary need to ensure Rab5 function even if aberrant 
mutations arise. However, it has been shown that they are differentially regulated in 
response to different stimuli and that phosphorylation could be responsible for a fine 
regulation of endocytosis in vivo due to the fact that each possess a common Ser/Thr 
kinase site (at position 123), but are differentially phosphorylated by specific kinases 
(ERK1 preferentially phosphorylating Rab5a, while p34cdc42 kinase preferentially 
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phosphorylating Rab5b) [Chiarielo et al., 1999]. As with other small GTPases, Rab5 
contains a highly conserved phosphate-binding loop (P-loop) made up of 
27GESAVGKS34 residues which have been shown to be important in GTP hydrolysis, 
whereas N and C termini are hypervariable. The C terminus is usually isoprenylated for 
targeting to particular membranes, as is the case with Rab5. Rab5 is very tolerable in its 
mutations at the N-terminus, meaning that the N terminal sequence is not an essential 
component required for Rab5 function, whereas mutations in the C terminus (especially 
the two cysteins of the CC
1.5.2 Guanine Nucleotide Exchange Factors 
SN tetrapeptide motif) eliminate the post-translational 
isoprenylation, membrane assosication and biological function of Rab5 [Li & Stahl, 
1993; Zhu et al., 2003]. 
Guanine Nucleotide Exchange Factors (GEFs) are proteins that activate small 
GTPases by catalyzing the exchanging of GDP by a GTP. All Rab5-GEFs contain a 
highly conserved Vps9 domain (Figure 3) through which they interact and activate Rab5. 
Some of the currently known Rab5-GEFs are Alsin, ALS2CL (ALS2 C-terminal-like 
protein), AnkRD27 (Ankyrin repeat domain containing protein 27), Rabex-5 (Rabaptin-5 
associated Exchange factor for Rab5), Rap6 (Rab5 activating protein 6), Rin1 (Ras 
interference/interaction 1), Rin2, Rin3 and RinL (Ras interference/interaction-like 
protein) (Figure 3) [Saito et al., 2002; Kajiho et al., 2003; Otomo et al., 2003; Hunker et 
al., 2006; Galvis et al., 2009; Jovic et al., 2010]. GTPase Activating Proteins (GAPs) 
speed up the intrinsic GTPase activity of Rab proteins, in turn inactivating them, and in 
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doing so allow Rab proteins to complex with their respective GDP-dissociation inhibitors 
(GDIs) in order to complete the cycle [Delprato et al., 2004]. 
1.5.2.1 Ras Interference/Interaction protein 
As other Rab5 GEFs, the Ras Interference/Interaction (Rin) group of proteins all 
contain a Vps9 domain (Figure 3), but also a Ras binding domain that facilitates allosteric 
regulation of Rab5 exchange activity by GTP bound Ras [Tall et al., 2001; Delprato et 
al., 2004]. The Rin1 protein also interacts with EGFR (and other receptor tyrosine 
kinases) via the SH2 domain, as well as Rab5 through the VPS9 domain, and since it acts 
as a Rab5GEF, it is plausible to assume that Rin1 plays a key role in recruitment of Rab5 
along with its subsequent activation through ligand dependent stimulation of EGFR (as 
well as other RTKs).  Furthermore, Rab5 and Rin1 localize to both plasma membrane and 
endosomes [Barbieri et al., 2003]. Pathologically, Rin1 has also been shown to enhance 
the oncogenic activity of BCR-ABL (Breakpoint cluster region protein-Abelson murine 
leukemia viral oncogene homolog 1) by interacting with the BCR-ABL fusion protein 
and hence speed up the BCR-ABL-induced leukemia in mice [Han et al., 1997; Delprato 
et al., 2004].  
1.5.2.2 Rabaptin-5 associated Exchange factor for Rab5 
Another well studied GEF for Rab5 is the Rabaptin-5 associated Exchange factor for 
Rab5 (Rabex-5), more commonly known as Rabex-5 (sometimes referred to as 
RabGEF1). David Lambright’s group has crystalized the Rabex-5 structure and identified 
it to be composed of an N-terminal A20 type zinc finger domain and a motif interacting 
with ubiquitin (MIU domain), a membrane binding domain, a helical bundle and a Vps9 
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domain (which together comprise the GEF catalytic core), and a C terminal coiled coil 
and proline rich domains (which form a complex with Rabaptin-5 and indirectly target 
Rabex-5 to early endosomes) (Figure 4) [Delprato et al., 2004; Aikawa, 2012; Shin et al., 
2012]. The same group also found that the amino acids D313, P317 and Y354 are all 
highly conserved among the Vps9 containing proteins, and that these residues are vital in 
maintaining full GEF activity of Rabex-5 [Delprato et al., 2004]. The discriminate 
binding of Rabex-5 to Rab5 lies in the requirement for a small non-acidic residue 
preceding F56 residue in the switch I-GxxF motif of Rab5. Substitution of this alanine 
with aspartic or glutamic acid (which are conserved in nearly all Rab GTPases) results in 
a 200-fold decline in catalytic efficiency.  Interestingly, in comparison to other GEFs, full 
length Rabex-5 has a very weak in vitro exchange activity, but increases tremendously 
when complexed to Rabaptin-5 or when only the helical bundle-Vps9 domain catalytic 
core is employed. One of the explanations for this could be the fact that regulatory 
elements which are found C-terminus (residues 415-425) can act as autoinhibitors of 
Rabex-5 GEF activity by overlapping the binding site for Rabaptin-5 [Delprato & 
Lambright, 2007]. It has been demonstrated that Rabex-5 activates Rab5 (through its 
catalytic core) and in doing so recruits Rabaptin-5, which then binds to the GTP bound 
form of Rab5 and recruits Rabex-5 in a positive feedback loop. This in turn stabilizes 
activated Rab5 on early endosomes and can therefore recruit other effector proteins of 
Rab5 (RabEP1-2 (Rab GTPase-binding effector proteins 1-2), ANKFY1 (Ankyrin repeat 
and FYVE domain-containing protein 1), MON1A-B (Monensin sensitivity protein 1), 
ZFYVE20 (zinc finger, FYVE domain containing 20), VPS34 (Vacuolar Sorting Protein 
34), EEA1 (Early Endosomal autoantigen 1), Rabenosyn-5, APPL1 (Adaptor protein 
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containing pleckstrin homolgy domain, PTB domain and leucine zipper Motif), APPL2) 
to the early endosome where specialized trafficking functions can be carried out [Jovic et 
al., 2010]. The Rabex-5 protein can also down regulate EGFR activity since it 
translocates to the plasma membrane after stimulation with EGF and colocalizes with 
EGFR at various stages of endocytosis through two distinct ubiquitin binding sites (A20 
zinc finger with E3 ubiquitin ligase activity and an inverted UIM (Ubiquitin interacting 
motif) with ubiquitin binding activity) [Lee et al., 2006; Penengo et al., 2007; Delprato & 
Lambright, 2007; Xu et al., 2010]. Rabex-5 has also been shown to inhibit Ras signaling 
via the ubiquitin ligase activity of ZnF domain and not the GEF domain [Colicelli, 2010; 
Yan et al., 2010]. Overexpression of Rabex-5 leads to an increased localization of Ras 
with EEA1 on endosomes, which has previously been shown to be a sign of Ras 
ubiquitination, while silencing Rabex-5 leads to inhibition of the aforementioned 
colocalization [Jura et al., 2006; Colicelli, 2010; Xu et al., 2010]. By restricting Ras 
signaling, Rabex-5 has been shown to be important in establishing organism size, wing 
vein pattern and eye versus antennal fate in Drosophila [Yan et al., 2010]. The same 
group has also shown that loss of Rabex-5 leads to death of flies as giant larvae or giant 
pupae often containing melanotic tumors [Yan et al., 2010]. Furthermore, Rabex-5-\- mice 
show a substantial increase in prenatal mortality, skin inflammation, increased numbers 
of skin mast cells and elevated serum levels of IgE and histamine [Tam et al., 2004; 
Delprato & Lambright, 2007]. 
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1.6 Disorders associated with aberrant activation of Rab5  
As Rab5 is a key regulator of the early endocytic process, it has been implicated in 
numerous diseases. First, Rab5 has been associated with DLB (Dementia with Lewy 
Bodies), since neuronal cell death has been associated with increased α-synuclein binding 
to Rab5a and its endocytosis, while expression of GTPase deficient Rab5a results in 
incomplete endocytosis of α-synuclein and therefore a decrease in cytotoxicity [Sung et 
al., 2001]. Second, Rab5b has been shown to reduce NMDA toxicity by up-regulating 
endocytosis of AMPA and NMDA receptors, which would thereby render these receptors 
ineffective and insensitive to excitotoxic stimulation [Baskys et al., 2007]. In Alzheimer 
pathology, Rab5 increases β–cleaved amyoloid precursor levels and Aβ production 
[Seabra et al., 2002]. When it comes to infections, it has been shown that in Listeria 
monocytogenes macrophage infections, Rab5 suppression enhances survival of Listeria, 
while overexpression has been shown to increase intracellular degradation of the 
pathogen [Hashim et al., 2000]. In Salmonella infections, it has been shown that 
phagosomes containing the internalized live bacteria acquire transferrin receptors and 
retain Rab5 and Rab18, and in doing so escape the default pathway to the lysosomes by 
associating with the late endosomes and maturing in specialized compartments [Hashim 
et a., 2000]. Lastly, Rab5 has also been implicated to be involved in cancer metastasis, 
amyotrophic lateral sclerosis 2 (ALS2), Long Term Depression (LTD), insulin resistance 
syndrome and Huntington’s disease [Bao et al., 1998; Yu et al., 1999; Hadano et al., 
2001; Devon et al., 2001; Pal et al., 2006; Baskys et al., 2007].  
Since Rab5 has been shown to be implicated in numerous devastating diseases, 
further research on both the mechanism of activation/inactivation as well as function of 
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this protein and its effectors should provide great insight into elucidating the pathogenesis 
of numerous diseases. Therefore, the aims of this dissertation will be to obtain a better 
understanding of Rab5 activation via tyrosine kinase receptor internalization, as well as 
thre role of its key activator Rabex-5 in two key biological processes, namely 
adipogenesis and neurogenesis. The completion of these aims will demonstrate that the 
tyrosine kinase activity of receptor tyrosine kinases is required for activation of Rab5; 
that Rab5 can be activated via at least 3 different endocytic pathways of EGFR 
internalization; and lastly, that Rabex-5, inhibits both adipogenesis (in 3T3-L1 cells) and 
neurogenesis (in PC12 and SK-N-MC cells) by promoting degradation of internalized 
signaling receptor (which under adipo- or neurogenic conditions is normally found inside 
a signalling vesicle), as well as through of Ras. Finally, this dissertation begins to explore 
the evolutionary redundancy of Rab5 activation, because three naturally occurring splice 
variants of Rabex-5 are accessible to activate Rab5 in a potential fail safe mechanism. 
Parts of this dissertation have been published in peer reviewed journals.  Chapter one 
contains work previously published in Jozic & Barbieri, 2010. On the other hand, Chapter 
two was published as two separate articles, one pertaining to to Insulin-Receptor (Jozic et 
al., 2011) and the other to EGF-Receptor (Jozic et al., 2012).  
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Figure 1. Pathways of EGF-Receptor Endocytosis. EGFR can be endocytosed through 
clathrin dependent or clathrin independent pathways (with the latter being composed of 
CavME and CLIC). Clathrin dependent endocytosis occurs predominantly when there is a 
low concentration of EGF at the cell surface and primarily results in recycling of EGFR 
via Rab5 dependent early endosome and recycling endosome.  Clathrin indendent 
pathways occur predominantly when there is a high concentration of EGF at the cell 
surface and primarily result in degradation of EGFR. If the pathway is dependent on 
caveolin the internalized vesicle will fuse with the early endosome in Rab5 dependent 
manner prior to fusing with the multivesicular body and then degraded in the lysosome. 
However, if the pathway is independent of caveolin, EGFR containing vesicle may 
bypass the Rab5-early endosome but is still destined for degradation in the lysosome.  
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Figure 2. Structure of Rab5 isoforms. All isoforms have highly conserved P-loop 
(residues 27-34), Switch 1 (residues 44-64) and Switch 2 (residues 76-94) regions but 
differ in their N- (residues 1-16) and C-terminal (residues 184-215) hypervariable 
domains. With the exception of an extra 19 aa fragment in Rab5c (149-164), the three 
isoforms exhibit an approximate 80% sequence homology, and are all isoprenylated at 
their C terminus.  
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Figure 3. Family of Vps9 domain containing proteins. ALS2 C-terminal-like protein 
(ALS2CL); AnkRD27 (Ankyrin repeat domain containing protein 27); Rabaptin-5 
associated Exchange factor for Rab5 (Rabex-5); Rab-activating protein 6 (Rap6); 
Rin1/2/3 (Ras interaction/interference protein) 1/2/3; Ras interaction/interference-like 
protein (RinL); Zinc Finger (ZF); Motif interacting with Ubiquitin (MIU); Membrane 
binding domain (MBM); Helical Bundle (HB); Vacuolar Sorting Protein 9 (Vps9); 
Coiled Coil (CC); Proline Rich (PR); Ankyrin1 (A); GTPase Activating protein for Ras 
(RasGAP); Regulator of Chromosome Condensation 1 (RCC1); Dbl Homology (DH); 
Pleckstrin Homology (PH); Membrane Occupation and Recognition Nexus repeat 
containing 1 (M); Src Homology 2 (SH2); Ras Association (RA). 
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Figure 4. Structure of Rabex-5 (RabGEF1). N-terminal A20 type zinc finger domain 
(ZF) and a motif interacting with ubiquitin (MIU domain) in tandem serve as an E3 
ubiquitin ligase; membrane binding domain (MBM); a helical bundle (HB) and a Vps9 
domain which together comprise the GEF catalytic core; C terminal coiled coil (CC) and 
proline rich (PR) domains which form a complex with Rabaptin-5 and indirectly target 
Rabex-5 to early endosomes. 
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CHAPTER 2 
TYROSINE KINASE ACTIVITY OF RECEPTOR TYROSINE KINASES IS 
REQUIRED FOR ENDOSOME FUSION AND ACTIVATION OF RAB5 
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2.1 Abstract 
Activation of receptor tyrosine kinases is a key feature in receptor signaling and 
membrane trafficking processes. Here, we established that the receptor tyrosine kinase 
activity is required for fusion between early endosomes. AG1024, insulin receptor 
tyrosine kinase inhibitor, and AG1478, EGF receptor tyrosine kinase inhibitor, both 
blocked the in vitro endosome fusion in a concentration-dependent manner. We observed 
that Rab5: wild type partially rescued the fusion reaction, whereas a GTP hydrolysis 
defective mutant (Rab5: Q79L) mutant fully rescued it. We also observed that treatment 
of cells with either insulin receptor kinase inhibitor HNMPA-(AM)3, or EGF receptor 
tyrosine kinase inhibitor AG1478, blocked the formation of Rab5-positive endosomes as 
well as the activation of Rab5 in intact cells upon stimulation with insulin or EGF 
respectively. Furthermore, we also found that upon stimulation with EGF, an EGF-
receptor catalytically inactive mutant failed to activate Rab5.  Furthermore, both 
HNMPA-(AM)3 and AG1478 inhibitors also affected the endosomal co-localization of 
Rab5 and insulin receptor or EGF receptor respectively. However, the formation of Rab5: 
Q79L mutant-positive endosomes were not affected by either tyrosine kinase inhibitor. In 
addition, both HNMPA-(AM)3 and AG1478 inhibitors affected the association of Rin1 to 
membrane upon insulin stimulation. Furthermore, Rin1 did not fully support endosome 
fusion in the presence of the tyrosine kinase inhibitors. Consistent with these 
observations, Rin1 was unable to localize to membranes upon stimulation with ligand in 
presence of a tyrosine kinase inhibitor. These results constitute the first evidence that, at 
least in part, the enzymatic activity of tyrosine kinase receptors (either insulin or EGF 
receptor) is required for the fusion events via the activation of Rab5. 
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2.2 Introduction 
 
The early endosome is a key check-point in endocytic pathways, in which a decision 
is made to either be sorted to the late endosome/lysosome compartment or to be recycled 
back to the plasma membrane [Doherty and McMahon, 2009; Pfeffer, 2007]. Rab5 and 
its effectors, including EEA1, Rin1, Rabaptin-5, RAP6 and Rabex-5, together with other 
small GTPases (i.e., Rab 4, 7, 11, 15 and 22), are likely to tightly control the fusion and 
sorting of molecules that have entered the early endosome [Sorkin and von Zastrow, 
2009; Scita and Di Fiore, 2010]. These homotypic and heterotypic vesicle fusions are 
regulated by several cytosolic and membranous factors. For example, the small GTPase 
Rab5 and its effectors regulate the fusion between early endosomes without affecting the 
fusion with late endosome or lysosomes. Thus, early endosome fusion is dependent on 
Rab5 proteins; it is symmetric and selective, thereby allowing orderly modification of 
ligand receptor interaction complexes and signaling in a sequential manner by altering the 
surroundings during receptor-ligand internalization [Bucci et al., 1992; Barbieri et al., 
1994; Li et al., 1995; Barbieri et al., 1998; Barbieri et al., 2000; Brandhorst et al., 2006]. 
In addition, several Rab5-asociated proteins are also required for endosome-endosome 
fusion [Li et al., 1995; Horiuchi et al., 1997; Simonsen et al., 1998; Christoforidis et al., 
1999; McBride et al., 1999; Nielsen et al., 2000; Lippe et al., 2001; Tall et al., 2001]. 
Endocytosis of the insulin receptor is initiated by the binding of its ligand [Russell et 
al., 1987; Khan et al., 1989; Liu and Roth, 1995; Di Guglielmo et al., 1998; Maggi et al., 
1998]. The insulin receptor-ligand complex is then transported through the endocytic 
pathway, where it is then either recycled back to the cell surface or transported to late 
endosomes, and ultimately, the lysosome for degradation [Siemeister et al., 1995; Waters 
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et al., 1995; Fucini et al., 1999]. The internalization of insulin receptors has been shown 
to be dependent on insulin receptor autophosphorylation, followed by the downstream 
phosphorylation and/or activation of insulin receptor substrate (IRS) or 
phosphatidylinositol 3 (PI3)-kinase through the clathrin-mediated pathway [Klein et al., 
1987; Carpentier et al., 1992; Carpentier et al., 1993]. However, other reports have also 
suggested other pathways for insulin receptor internalization [Fan et al., 1982; Smith & 
Jarett, 1990; Paccaud et al., 1992]. We have taken advantage of the well-characterized 
trafficking pathway of the activated insulin receptor [Fan et al., 1982; Klein et al., 1987], 
in order to measure fusion of insulin–insulin receptor vesicles (internalized Biotin-
insulin) with other endocytic vesicles that have been prepared by internalizing Avidin-β-
galatosidase during fluid phase endocytosis in HepG2 cells. By allowing different 
populations of HepG2 cells to engage in receptor-mediated endocytosis of insulin linked 
to biotin and fluid phase endocytosis of Av-β-galatosidase, we are able to isolate donor 
and acceptor pools of endosomes, and examine for endosome fusion as previously 
developed cell-free endosome fusion assays [Braell, 1987; Gruenberg & Howell, 1986; 
Mayorga et al., 1988; Wessling-Resnick & Braell, 1990; Gorvel et al., 1991; Mullock and 
Luzio, 1992; Rubino et al., 2000].  
Along the same lines, interaction of epidermal growth factor (EGF) [Citri & Yarden, 
2006] with EGF receptors leads to activation and tyrosine autophosphorylation of the 
receptor, which in turn creates binding sites for proteins containing Src homology 2 
(SH2) and phosphotyrosine-binding domains (PTB) [O’Bryan et al., 1998]. 
Consequently, the activation of EGF-receptor dramatically accelerates endocytosis of 
EGF-receptor complexes through clathrin-coated pits [Huang & Sokin, 2005]. Several 
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factors affect the endocytosis of activated EGF-receptors, including Shc, Grb2, Cbl, 
Rab5, and PI3-kinase [O’Bryan et al., 1998; Burke et al., 2001; Huang & Sorkin, 2005]. 
After internalization, EGF-receptors are efficiently sorted to the lysosomal compartment 
via early and late endosomes. Hence, increased internalization and lysosomal targeting, 
results in down-regulation of EGF-receptor and leads to attenuation of the growth factor 
signaling cascade [Burke et al., 2001]. In addition, several Rab5-asociated proteins are 
also required for endosome–endosome fusion [Li et al., 1995; Horiuchi et al., 1997; 
Simonsen et al., 1998; McBride et al., 1999; Christoforidis et al., 1999; Nielsen et al., 
2000; Lippe et al., 2001; Tall et al., 2001]. Given the importance of tyrosine 
phosphorylation in both signaling and trafficking of growth factors, specific and selective 
inhibitors of tyrosine kinase activity are important tools for studying EGF-receptor 
function [Burke et al., 2001; Sorkina et al., 2002; Citri et al., 2006; Doherty et al., 2009]. 
Therefore, the analysis of the effects of tyrosine kinase inhibitors on EGF-receptor 
trafficking and signaling may provide important information about the mechanisms by 
which the inhibitor(s) function(s) at the cellular level. 
Here, we demonstrate that tyrosine kinase activity of two different RTKs (insulin and 
EGF-receptor) is required for the formation for enlarged Rab5-positive endosomes as 
well as for the activation of Rab5 in intact cells. We also observed that tyrosine kinase 
inhibitors (AG1024 and HNMPA-(AM)3 for insulin receptor and AG1478 for EGF 
receptor) blocked endosome fusion, whose inhibitory effect was linked to the activation 
of Rab5. Furthermore, we found that tyrosine kinase inhibitors of either receptor blocked 
the endosome fusion reaction stimulated by Rin1. More importantly, we have also 
observed that the addition of a constitutively active mutant of Rab5 (e.g., Rab5:Q79L), 
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reversed the inhibitory effect of each inhibitor, suggesting a mechanism by which the 
tyrosine kinase activity of the receptor modulates early endosome fusion. 
 
2.3 Materials and Methods 
 
2.3.1 Cell Culture and Materials 
HepG2 cells (American Type Culture Collection) were grown to confluence in 
Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine serum. 
NIH3T3-human insulin receptor (NIH-IR) cells, NR6 cells expressing the human EGF-
receptor (NR6-E) and human EGF-receptor catalytically inactive mutant (K712M) (NR6-
K) were all grown in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal 
bovine serum containing 0.3-0.5 mg/ml G418. Kinase inhibitors were purchased from 
EMD Biosciences (La Jolla, CA). EEA-1, Rab5, Rab11, P-Y100 and Rabex-5 antibodies 
were from Cell Signaling Technology (Beverly, MA). Rin1 antibodies were from Abcam 
Inc. Biotin-insulin and Avidin β-galactodidsase and the anti-insulin antibodies were 
purchased from Sigma-Aldrich (St. Louis, MO). All secondary antibodies were 
purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). All other 
chemicals were obtained from Sigma unless otherwise stated. 
2.3.2 Endocytic Probes and Fractionation 
HepG2 cells were collected by centrifugation, washed three times in Hank's balanced 
salt solution (HBSS) with 15 mM HEPES and supplemented with 1 mg /ml BSA (HBSS-
BSA, pH 7.0). Endocytosis of probes was performed with cells suspended in HBSS-BSA 
buffer. To prepare early endosomes loaded with Biotin-Insulin or Avidin-β-galatosidase, 
cells (8 x 108/ml) were allowed to internalize either 1 mg/ml Avidin-β-galatosidase or 
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Biotin-Insulin 100 ng/ml for 5 min at 37°C in order to prepare the endosome fractions. 
The cells were then washed in uptake media at 800 x g, followed by two more washes, 
once in HBSS-BSA buffer and once in homogenization buffer (HB, 0.25 M sucrose, 20 
mM HEPES, 0.5 mM EGTA, pH 7.0). Cells were then resuspended in homogenization 
buffer (4 x 108/ml) and passed 17 times through a stainless steel ball homogenizer. The 
homogenate was centrifuged at 800 x g for 10 min to generate a post nuclear supernatant 
(PNS). Typical homogenization yielded >80% of endocytosed marker in the PNS as 
determined by either radioactivity or immunoprecipitation of ligand. PNSs could then be 
used fresh for fractionation studies, cytosol preparation, or stored frozen in liquid 
nitrogen for later use (Gruenberg and Howell, 1986). 
2.3.3 Fusion Assay 
Two populations of vesicles containing Avidin-β-galatosidase and either Biotin-
Insulin or Biotin-EGF were mixed at 4°C to a final volume of 11 μl in fusion buffer (250 
mM Sucrose, 0.5 mM EGTA, 1 mM DTT, 1.5 mM MgCl2, 50 μg/ml B-BSA, 50 mM 
KCl, and 20 mM HEPES-KOH, pH 7.0). The buffer was supplemented with a 
regenerating system (1 mM ATP, 8 mM creatine phosphate, 31 units/ml creatine 
phosphokinase) or with a depleting system (5 mM mannose, 25 units/ml hexokinase). 
AG1024 and AG1478 inhibitors as well as AG9, an inactive analog, were added to the 
reaction at the concentration indicated in each figure. After incubation at 37°C for 45-
min, the fusion reaction was stopped by cooling to 4°C (ice) for 10 min. To measure the 
immune complexes formed, the vesicles were solubilized by adding 150 μl of 
solubilization buffer (1% Triton X-100, 1 mM EDTA, 0.1% BSA, 0.15 M NaCl, 10 mM 
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Tris-HC1, pH 7.4) containing 35 μg/ml Biotin-BSA. Biotin-BSA was used to quench any 
free Av-Gal due the presence of broken endosomes during the homozenization process. 
The solubilized samples were then added to wells that were plate coated with anti-insulin 
antibody. After a 60-min incubation period at 4°C, immunoprecipitates were washed 
twice with 200 μl of solubilization buffer and the β-galactosidase activity was measured 
by using 4-methylumbelliferyl-D-galactoside substrate [Mayorga et al., 1988]. There was 
a linear relationship between the amount of immunoprecipitate added to the enzymatic 
assay and the amount of product formed. Fusion-dependent immunoprecipitable 
enzymatic activity was expressed as a percent of the total immunoprecipitable activity in 
the assay. Total activity was determined by immunoprecipitating the immune complexes 
after mixing vesicles in the presence of detergent but in the absence of Biotin-BSA.  
2.3.4 Electron microscopy 
Colloidal gold particles of 10 and 20 nm were obtained from Sigma. Gold particles 
were coated with proteins (insulin and β-galactosidase) by standard techniques [Mayorga 
et al., 1989]. Binding and uptake of gold particles coated with the ligands were carried 
out under the similar conditions described by Mayorga et al., 1989 for soluble ligands 
into two separate populations of HepG2 cells by 5-min incubated at 37ºC. The 
homogenization of cells and the fusion reaction were performed using the same protocols 
described above, except that both homogenization and fusion buffers were buffered with 
30 mM MES, pH: 6.6. They were centrifuged, and then the vesicles were mixed under 
fusogenic conditions. After the incubation, the fusion reaction was then stopped by 
adding 1% glutaraldehyde, which was prepared in HB buffer at room temperature. After 
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10 min, samples were centrifuged for 15 min at 12,000 x g, washed and the samples were 
processed by transmission electron microscopy [Mayorga et al., 1989]. 
2.3.5 Western Blot Analysis 
Lysate Preparation, SDS-PAGE, and Western Blotting: To prepare whole cell lysates, 
cell were washed twice with ice-cold PBS and lysed in ice-cold lysis buffer (20mM Tris- 
HCl pH 7.5, 150mM NaCl, 1% Triton X-100). The lysates were clarified by 
centrifugation, and protein concentrations were determined using the BCA Protein Assay 
Reagent Kit (Pierce). Proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes, which were blocked and probed with the indicated antibodies. 
To determine relative protein amounts, three representative exposures for each sample 
were quantified using National Institutes of Health ImageJ software. 
2.3.6 Confocal microscopy 
NR6-E, NR6-K or NIH3T3-human insulin receptor cells were seeded on glass 
coverslips at 1.0 × 105 per 3.8 cm2 well. The following day, cells were transfected using 
FugeneHD with either pEGFP-Rab5: WT or pEGFP-Rab5: Q79L. Cells were starved in 
serum-free Dulbecco's modified Eagle's medium supplemented with 5% BSA Fraction V 
(MP Biomediclas, Solon, OH) for 14 hours, and treated as indicated with 100 μM AG9, 
100 μM HNMPA-(AM)3 or 100nM AG1478 for 30 minutes at 4oC, after which they were 
treated with either EGF or Insulin at 100 ng/ml for 1hr at 4oC and then stimulated to 
uptake the ligand for 5 min at 37oC. They were washed with PBS and fixed in 4% 
paraformaldehyde for 20 minutes. Fixed cells were probed with rabbit polyclonal insulin 
receptor antibodies for 1h. Secondary antibodies used were Alexa594-conjugated goat 
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anti-rabbit IgG. Coverslips were mounted with Prolong and viewed on a Leica TCS SP2 
confocal microscope. 
2.3.7 Statistical analysis 
All experiments presented were repeated at least three times. The data represent the 
mean ± SD calculated using Excel. Student’s t-test was performed to calculate statistical 
significance. 
 
2.4 Results 
 
2.4.1 Insulin receptor tyrosine kinase inhibitor blocks in vitro endosome fusion 
 
To prepare endosomes, 0.1μg /ml Biotin-insulin and 2mg/ml Avidin-β-Galactosidase 
were separately internalized for 5 min at 37°C in HepG2 cells as described in Materials 
and Methods. When the isolated vesicles containing Biotin-Insulin were mixed with 
vesicles containing Avidin-β-Galactosidase in an in vitro system in the presence of an 
ATP regenerating system at 37ºC, a cytosolic-dependent increase of complex formation 
was observed (Figure 5A). The effect of cytosol appeared to be saturable at about 1.0 
mg/ml protein and no fusion activity was observed without cytosol. As expected, in the 
presence of ATP-depleting system, very little fusion activity was observed (Figure 5A). 
Furthermore, the fusion was also time-dependent (Figure 6A). 
To examine the specificity of the fusion assay, different populations of vesicles were 
employed. First, Biotin-insulin was internalized for 3 min at 37°C. Second, Avidin-β-
Galactosidase was internalized by cells for 3 min and then chased for 0, 3, 6, or 12 min to 
load the later compartments at 37°C (Figure 6B). Since the maximum fusion activity was 
observed when both probes were present at 3-min endosomes, we then examined fusion 
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of such vesicles containing Biotin-insulin. As Avidin-β-Galactosidase was chased for an 
extended period of time, ATP-dependent fusion activity decreased rapidly (Figure 6B). 
After a 12-min chase, fusion activity was reduced by 70% and no fusion activity was 
detected when Av-Gal was chased for 30 min (data not shown). These results indicate 
that fusion between Biotin-Insulin and Avidin-β-Galactosidase containing vesicles 
requires ATP, cytosolic proteins and is also time-dependent. The endosome reaction was 
affected by the ionic strength of the fusion buffer. The optimum concentration of KCl 
was 60 mM as is the case in reconstitution studies with intracellular vesicular transport 
[Mayorga et al., 1989]. The in vitro endosome fusion assay showed similar requirements 
with other in vitro vesicle fusion systems (i.e., ATP, cytosol proteins, and salts). We also 
investigated the requirements of the small Rab5 in this in vitro assay since Rab5 is a 
critical regulator of the early endosome fusion [Bucci et al., 1992]. In Figure 6C, we 
show that the addition of cytosol depleted of Rab5 inhibited the endosome fusion. In 
contrast, the cytosol treated with control IgG or depleted of Rab11 and Rab4 did not 
affect the fusion reaction. Clearly our results indicate the specificity of the fusion reaction 
and more importantly, that this in vitro system is Rab5-dependent. We then confirmed the 
requirement of Rab5 in this in vitro system by observing that the addition of GDI to the 
in vitro system blocked the fusion reaction (Figure 6C). Thus, the requirement of Rab5 in 
this in vitro system raises the question whether Rab5 interacting proteins were also 
required in this endosome fusion system. 
We examined the requirement of Rin1, a Rab5-guanine exchange factor, or other 
effectors (i.e., EEA1) in the fusion reaction. As shown in Figure 6C the depletion of Rin1 
or EEA1 from the cytosol and the subsequent fusion reaction, showed an inhibitory 
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effect. We also found that the addition of inactive fragment of Syntaxin 13 inhibited the 
fusion reaction (Figure 6C). These observations further confirmed that our in vitro fusion 
reaction was SNARE-dependent, as previously determined for the heterotypic fusion 
between clathrin coated vesicle and early endosomes, and homotypic fusion between 
early endosomes [Rubino et al., 2000]. Because PI3-kinase and NSF activities have been 
shown to regulate the fusion reaction, we investigated the role of these two activities in 
the fusion reaction by incubating endosomes in the presence of NEM (a NSF inhibitor), 
or Wortmannin (a PI3-kinase inhibitor). As shown in Figure 6C, the addition of 1 mM 
NEM and 100 nM Wortmannin strongly inhibited the fusion reaction. Taken together, 
these results indicate that the fusion between endosomes containing Biotin-insulin and 
Avidin-β-Galactosidase was mediated by a specific fusion event whose characteristics are 
similar to those described in other endosome-endosome fusion reactions [Gruenberg and 
Howell, 1986; Braell, 1987; Mayorga et al., 1988]. As described above, our data indicate 
that different activities (i.e., Rab5, Rin1, and PI3-K) are required in this novel fusion 
reaction between endosomes. Interestingly these activities have also been linked to the 
activated insulin receptor, including the formation of enlarged Rab5-positive endosomes 
in intact cells upon addition of insulin [Hunker et al., 2006b]. Therefore, we raised the 
question whether the tyrosine kinase activity of the insulin receptor was also required in 
the fusion between endosomes. To investigate this requirement, we first examined the 
effect of AG1024, an insulin receptor tyrosine kinase inhibitor (Parrizas et al., 1997) on 
the fusion reaction. As a control, we also examined the effect of an inactive tyrosine 
kinase inhibitor (AG9). When the fusion reaction was conducted in the presence of 
AG1024, we found a strong inhibition of the fusion reaction in a concentration dependent 
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manner (Figure 5B). However, the addition of AG9 did not affect the fusion reaction, 
which suggests that this inhibitory effect was specific. 
A similar protocol was followed to examine the endosome-endosome fusion 
morphologically. In these experiments, 20 nm colloidal gold coated with Biotin-insulin 
and 10 nm colloidal gold coated with Avidin-β-Galactosidase were localized in 5-min 
endosomes. These endosomes were incubated under standard fusogenic conditions and 
the vesicle pellets were then processed and observed by electron microscopy as described 
in Material and methods. As shown in Figure 7A, we observed vesicle fusion in the 
presence of cytosol at 37°C containing an ATP-regenerating system, evidenced by the 
presence of varying sized of gold particles within an endosome. However, we did not 
observe vesicle fusion when the vesicles were incubated in the presence of cytosol either 
at 4°C (Figure 7B) or in the presence of 20 μM AG1024 kinase inhibitor (Figure 7C). We 
also determined the number of vesicles containing more than one size of gold particles 
within an endosome under several experimental conditions. After fusion reactions, we 
observed that 25 ± 4 % of the endosomes contained two different sizes of gold particles 
when the endosomes were incubated in the presence of cytosol supplemented with ATP 
(Figure 7D, line 2). However, in the absence of ATP at 37°C (Figure 7D line 1) or at 4°C 
(Figure 7D, line 4), or the addition of AG1024, we observed a strong inhibition of 
formation of endosomes containing two different sizes of gold particles (Figure 7D line 
3).  Because the fusion reaction required Rab5 and was also inhibited by AG1024, we 
tested whether AG1024 inhibitor would affect the endosome fusion stimulated by Rab5. 
Early endosome and cytosol preparations were pre-incubated with 20 μM of AG1024 for 
15 min prior to the initiation of the fusion reaction at 4°C. It was seen that AG1024 
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partially inhibited early endosome fusion in the presence of Rab5: wild type. However, 
addition of Rab5: Q79L reversed the inhibitory effect of AG1024 inhibitor and stimulated 
endosome fusion (Figure 8). Therefore it is unlikely that the inhibition by AG1024 was 
due to nonspecific damaging of endosomal membranes.  
Altogether, these observations may establish a potential role of the insulin receptor 
tyrosine kinase activity on the activation of the fusion reaction that is mediated by Rab5. 
Based on our initial observation, that Rab5:WT partially restored the fusion reaction 
affected by AG1024, and the fact that Rin1 stimulated endosome fusion, we then further 
examined the role of AG1024 inhibitor on the fusion reaction by investigating whether 
AG1024 inhibitor affects the endosome fusion stimulated by Rin1. In Figure 9, we 
showed that Rin1 stimulated endosome fusion in a concentration-dependent manner. 
However, Rin1 partially restored the inhibitory of AG1024. Taken together, these 
observations indicate that tyrosine kinase activity of insulin receptor plays, at least in 
part, an important role in Rin1-mediated endosome fusion.  
2.4.2 Insulin receptor inhibitor blocks fusion between endosomes in intact cells. 
Given the effect of AG1024 inhibitor on the in vitro Rab5-dependent fusion between 
endosomes, we examined whether the addition of insulin receptor tyrosine kinase 
inhibitor HNMPA-(AM)3 affects the changes in the Rab5 distribution and/or localization 
upon insulin stimulation in intact cells. HNMPA-(AM)3 is a cell-permeable and selective 
insulin receptor tyrosine kinase inhibitor analog of HNMPA [Saperstein et al., 1989]. For 
this purpose, we prepared cell lines expressing Rab5: wild type and Rab5: Q79L mutant, 
respectively. These cell lines were then treated 10 min with 100 ng/ml insulin in the 
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absence or presence of 100 μM HNMPA-(AM)3 inhibitor. After the incubation, cells 
were processed for immunofluorescence microscopy as described in Materials and 
Methods. As expected, in the absence of insulin, Rab5: wild type appears in diffuse and 
typically punctuate endosomal structures (Figure 10A-C). However, upon addition of 
insulin, Rab5: wild type was found in enlarged vesicles (Figure 10D-F). The sizes of 
these enlarged Rab5-positive endosomes were comparable to the endosomal size 
observed in cells expressing Rab5: Q79L mutant (compare Figure 10D-F with Figure 
11M-X). Interestingly, in cells stimulated with insulin and treated with HNMPA-(AM)3 
inhibitor, we observed a significant decrease in size of Rab5-positve endosomes in cells 
expressing Rab5: wild type (Figure 10J-L), but not in cells expressing Rab5: Q79L 
mutants (Figure 11VX). These observations are consistent with our in vitro endosome 
fusion data, in which the addition of Rab5: WT, but not Rab5: Q79L mutant, partially 
supported the fusion reaction in the presence of insulin receptor tyrosine kinase inhibitor 
(Figure 8). We also observed that insulin receptor co-localizes with Rab5 on endosomes 
when cells were stimulated with insulin in the absence of HNMPA-(AM)3 inhibitor 
(Figure 10D-F), but not in the presence of the inhibitor (compare Figure 10D-F and 10J-
L). Furthermore, analysis of Rab5: WT in cells stimulated with insulin in the presence of 
inhibitor showed a more diffuse (primary cytosolic) pattern, that is comparable with the 
distinct distribution of Rab5: wild type in the absence of insulin (compare Figure 10A-C 
and 10J-L). In contrast, in cells expressing Rab5: Q79L mutant, the addition of HNMPA-
(AM)3 inhibitor failed to affect the formation of significantly enlarged Rab5:Q79L 
mutant-positive endosomes (compare Figure 11P-R and 11V-Y). Moreover, we observed 
that the internalized insulin receptor also co-localized with Rab5: Q79L mutant-positive 
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endosomes, when cells were treated with HNMPA-(AM)3 inhibitor (Figure 11P-R and 
11VY). These results suggest that the formation of these enlarged Rab5: Q79L-positive 
endosomes as well as the localization of insulin receptor were independent of the 
activation of the insulin receptor. 
2.4.3 HNMPA-(AM)3 inhibitor blocks Rab5 activation and targeting of Rin1 to membrane 
upon insulin stimulation 
 
To examine the role of insulin receptor on the activation of Rab5 upon stimulation of 
insulin, cells expressing either Rab5: WT or Rab5: Q79L mutant were incubated with or 
without HNMPA-(AM)3 inhibitor in the absence or presence of insulin. After incubation, 
Rab5 GTP-bound form was precipitated with GST-EEA1/N domain, as described in the 
Materials and Methods. As shown in Figure 12A, the addition of HNMPA-(AM)3 
inhibitor significantly diminished the amount of Rab5-GTP bound form when cells 
expressing Rab5: wild type were stimulated with insulin. However, in cells expressing 
Rab5: Q79L, the addition of HNMPA-(AM)3 inhibitor did not exhibit any effect at all 
(Figure 12B). Insulin receptor’s activation leads to autophosphorylation, which is 
followed by the downstream phosphorylation of IRS [Fan et al., 1982; Russell et al., 
1987] and association of molecules such as Grb2 [Liu and Roth, 1995] and Rin1 [Hunker 
et al., 2006a] through the clathrin mediated pathway. To further examine whether the 
insulin receptor kinase activity is linked to the membrane targeting to Rin1, the effect of 
HNMPA-(AM)3 inhibitor was evaluated to determine whether this nucleotide exchange 
factor for Rab5 was targeted to membranes upon insulin stimulation. In Figure 13, we 
show that insulin receptor was tyrosine phosphorylated in the presence, but not in the 
absence, of insulin. Furthermore, insulin receptor was found associated to membranes, 
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which indicates that the integrity of the isolated membrane fraction. IRS-1 and Grb2 were 
associated with membranes upon insulin stimulation. However, the addition of HNMPA-
(AM)3 inhibitor partially blocked the membrane association of these molecules. 
Interestingly, Rin1 was also associated with membrane upon insulin stimulation, but not 
in the presence of HNMPA-(AM)3 inhibitor. We also examined the effect of HNMPA-
(AM)3 inhibitor on the distribution of Rabex-5, another Rab5-GEF. As shown in Figure 
13, Rabex-5 was recruited to the membrane upon stimulation with insulin. However, the 
addition of HNMPA-(AM)3 upon stimulation with insulin had no effect on the 
recruitment of Rabex-5 to the membrane. Taken together, these results are consistent with 
the observation that HNMPA-(AM)3 blocked the activation of Rab5 via Rin1 in intact 
cells. 
2.4.4 EGF-receptor tyrosine kinase inhibitor blocks fusion between endosomes in intact 
cells 
 
EGF-receptor activation leads to tyrosine autophosphorylation of the cytoplasmic tail 
and the subsequent recruitment of several factors including Shc, Grb2, PLC-c, Rin1 and 
Rabex-5 [Wells et al., 1999; Wiley 2003; Hayes et al., 2004]. To determine whether 
EGF-receptor kinase activity directly affects the activity of Rab5 in intact cells, we 
examined whether the addition of AG1478 inhibitor affects the changes in distribution 
and/or localization of Rab5 upon stimulation of EGF in intact cells. As expected, in the 
absence of EGF, Rab5:WT appears diffuse and typically in punctuate endosomal 
structures (see arrows in Figure 14C). However, upon addition of EGF, Rab5:WT was 
found in enlarged vesicles (see arrows in Figure 14F). In these cells, the enlarged Rab5-
positive endosomes were comparable in size to those endosomes observed in cells 
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overexpressing Rab5:Q79L mutant (compare Figure 14F with Figure 15A–R). 
Furthermore, we observed a significant decrease in size of Rab5-positive endosomes in 
cells expressing Rab5:WT when treated with AG1478 (Figure 14L), but not in cells 
expressing the Rab5:Q79L mutant (Figure 15G–L). We also observed that in the absence 
of AG1478 inhibitor, EGF-receptor co-localizes with Rab5 on endosomes when cells are 
stimulated with EGF, but not in the presence of the inhibitor (compare Figure 14F and 
Figure 14L). However, in cells expressing the Rab5:Q79L mutant, addition of the 
AG1478 inhibitor failed to affect either the formation of enlarged Rab5-positive 
endosomes or the co-localization of internalized EGF-receptor with Rab5:Q79L mutant-
positive endosomes, when cells were treated with the AG1478 inhibitor (Figure 15). In 
addition, we found that in the absence or in the presence of EGF, Rab5:WT appears 
diffuse and typically in punctate endosomal structures in cells expressing EGF-receptor 
catalytic inactive mutant (see arrows in Figure 14O–R). In contrast, we found enlarged 
Rab5-positive endosomes in cells expressing both Rab5:Q79L mutant and EGF-receptor 
catalytically inactive mutant (Figure 15O–R). As expected, EGF-receptor:WT, but not 
the catalytically inactive mutant of EGF-receptor, was tyrosine phosphorylated in the 
presence of EGF in these cells (Figure 16). These observations are consistent with the 
idea that the EGF-receptor kinase activity is required for formation of enlarged Rab5-
positive endosomes as well as the subsequent co-localization for Rab5 and EGF-receptor 
on the endosomes. Thus, it is possible to speculate that the AG418 inhibitor should alter 
the size distribution of endosomes in cells expressing Rab5:WT, but not in cell 
expressing Rab5:Q79L mutant. To test this hypothesis, we expressed GFP-Rab5:Q79L 
and GFPRab5:WT proteins respectively in NR6 cells. Rab5-positive endosomes were 
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identified by confocal immunofluorescence microscopy and then quantified using the 
NIH Image J software. We observed that in NR6-E cells expressing Rab5:WT, the 
endosomes were generally smaller with an average perimeter of 1.51 µm (or 0.48 µm in 
diameter) and a relative variance of 1.70 In contrast upon stimulation with EGF, Rab5-
positive endosomes were enlarged with an average perimeter of 3.29 µm (or 1.05 µm in 
diameter) and a relative variance of 1.41 (Figure 17A).We also observed that the addition 
of AG418 inhibitor to NR6-E cells expressing Rab5:WT, which were then stimulated 
with EGF, clearly decreased size of the endosomes (average perimeter of 1.69 µm [or 
0.54 µm in diameter] and a relative variance of 1.61) (Figure 17B). As expected, the 
addition of AG9 an inactive analog, did not affect neither endosome size nor endosome 
distribution (Figure 17A, B). These observations are in agreement with the inhibitory 
effect of AG418 on the activation of Rab5 in NR6-E cells upon stimulation of EGF. 
Importantly, we observed that in NR6-E cells expressing Rab5: Q79L the size 
distribution of the endosomes showed an average perimeter of 5.74 µm (or 1.83 µm in 
diameter) and a relative variance of 1.44 and were not affected by the addition of either 
EGF or AG418 inhibitor (Figure 17C). These observations are consistent with the fact 
that the amount of GTP-bound form of Rab5 was not affected in NR6-E cells expressing 
Rab5:Q79L mutant. 
Lastly, we observed that in NR6-K cells expressing Rab5:Q79L, the size distribution 
of the endosomes were comparable to those observed in NR6-E cells expressing 
Rab5:Q79L (Figure 17D). Furthermore, when EGF was added to NR6-K cells expressing 
Rab5:WT, Rab5-positive endosomes were not enlarged (average perimeter of 1.60 µm 
[or 0.51 µm in diameter], and a relative variance of 1.71) (Figure 17D). Taken together, 
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this quantitative difference between Rab5:WT either in the absence or in the presence of 
EGF, are significant, especially reflected by the extended tail of Rab5:WT endosome 
distribution in cells stimulated with EGF.  
2.4.5 AG1478 inhibitor blocks the activation of Rab5 in intact cells  
To further examine the role of EGF-receptor kinase activity on the activation of Rab5 
upon stimulation with EGF, cells expressing either Rab5:wild type or Rab5:Q79L mutant 
were incubated with or without the AG1478 inhibitor in the absence or presence of EGF. 
After incubation, active or GTP-bound form of Rab5 was precipitated with GST-EEA1 
domain as described in Materials and methods. As shown in Figure 18A, the addition of 
AG1478 inhibitor significantly diminished the amount of GTP-bound form of Rab5 when 
the cells expressing both Rab5:WT and EGF-receptor: wild type were stimulated with 
EGF. However, addition of the AG1478 inhibitor to cells expressing the Rab5:Q79L 
mutant had no effect at all (Figure 18B). Furthermore, we also found that in cells 
expressing EGF-receptor catalytically inactive mutant and Rab5:WT, Rab5 was not 
activated and the catalytically inactive mutant of EGF-receptor was not tyrosine 
phosphorylated upon addition of EGF (Figure 18A and B). These data demonstrate that 
the inhibition of the EGF-receptor activity is linked to the inactivation of Rab5. 
2.4.6 EGF-receptor tyrosine kinase inhibitor blocks the recruitment of Rin in intact cells 
Given the effect of AG1478 inhibitor on the activation of Rab5 in intact cells, we 
examined whether the addition of AG1478 inhibitor can affect the changes in membrane 
distribution of several factors associated with EGF-receptor:WT, upon stimulation with 
EGF in intact cells. As expected, either in the absence or presence of EGF, EGF-receptor 
was always found in the membrane fraction (Figure 19A). EGF-receptor was also 
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tyrosine phosphorylated only in the presence of EGF, while the addition of the AG1478 
inhibitor blocked the phosphorylation of EGF-receptor (Figure 19A). Consistent with this 
data, in the absence (but not in presence) of AG1478 inhibitor, Shc and Grb2 were 
recruited to the membrane fraction upon stimulation with EGF (Figure 19B and C). 
Furthermore, Rin1 was recruited to the membrane upon EGF stimulation. In contrast, 
Rin1 was poorly localized on the membrane in the presence of AG1478 and upon 
stimulation with EGF (Figure 19D). Interestingly, Rin1 was also tyrosine phopshorylated 
upon EGF stimulation (Figure 20), but not in the presence of AG1478 inhibitor and in 
cells expressing EGF-receptor catalytically inactive mutant. As an extension of our 
observation, we also investigated the effect of AG1478 inhibitor on the membrane 
distribution of Rabex-5. As shown in Figure 3E, Rabex-5 was recruited to the membrane 
upon stimulation with EGF. However, the addition of AG1478 upon stimulation with 
EGF had no effect on the recruitment of Rabex-5 to the membrane. These data 
demonstrate that in addition to being able to block the recruitment of Shc and Grb2 
factors, the inhibition of the tyrosine kinase activity of EGF-receptor is linked to a 
selective membrane targeting of Rin1. Consistent with these observations we found that 
Rin1, Rabex-5 and Shc were not translocated to membranes upon EGF stimulation in 
cells expressing EGF-receptor catalytically inactive mutant (Figure 20). As expected, 
EGF receptor catalytically inactive mutant was not tyrosine phosphorylated upon addition 
of EGF (Figure 21). Taken together, these observations suggest that both Rin1 and 
Rabex-5 are targeted to membrane upon EGF stimulation but they are not translocated 
either in cells expressing EGF-receptor catalytically inactive mutant or selectively 
affected in the presence of AG1478 inhibitor. 
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2.4.7 EGF-receptor tyrosine kinase inhibitor inhibits in vitro endosome fusion 
We have previously demonstrated that different factors (i.e., Rab5, Rin1 and PI3-
kinase) were required for the fusion reaction between endosomes containing EGF-
receptor [Tall et al., 2001]. Interestingly, these activities have also been linked to the 
activated EGF-receptor, which in turn involve the formation of enlarged Rab5-positive 
endosomes in intact cells upon stimulation with EGF [Barbieri et al., 2000]. Therefore, 
we raised the question of whether tyrosine kinase activity of the EGF-receptor is also 
required in the fusion between endosomes. To investigate this requirement, we first 
examined the effect of AG1478 inhibitor [Yamamoto et al., 2006; Kondratov et al., 2010] 
on the fusion reaction. As a control, we also examined the effect of an inactive tyrosine 
kinase inhibitor (AG9). Five-min vesicles containing either Biotin (B)-EGF or 
Avidin(Av)-GAL were mixed in fusion buffer supplemented with 1 mg/ml of cytosol 
containing an ATP-regenerating system either in the absence or in the presence of 
different concentrations of AG9 and AG1478 (Figure 22A). Samples were then 
transferred to 37oC for the indicated times and processed as described in Materials and 
methods to determine the percentage forming the immune complex. When the fusion 
reaction was conducted in the presence of AG1478, we observed a strong inhibition of 
the fusion reaction that occurred in a concentration dependent manner. However, the 
addition of AG9 did not affect the fusion reaction in comparison to the control, which 
argues for the specificity of the exhibited inhibitory effect (Figure 22A). 
Because of the inhibitory pattern of AG1478 exhibited in the fusion reaction (Figure 
4A) and because Rab5 is a key factor required for fusion between endosomes directed by 
the EGF-receptor [Bucci et al., 1992; Barbieri et al., 1994], we tested whether the 
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AG1478 inhibitor would affect endosome fusion stimulated Rab5. Early endosome and 
cytosol preparation were pre-incubated with 20 µM AG1478 for 15 min prior to the 
initiation of the fusion reaction. The addition of AG1478 inhibited early endosome fusion 
in the presence of Rab5:WT, however, the addition of Rab5:Q79L mutant reversed the 
inhibitory effect and thus stimulated endosome fusion (Figure 22B). On the basis of 
previous data [Tall et al., 2001; Hunker et al., 2006] and the results reported here, we 
then investigated the effect of the tyrosine kinase enzymatic activity of the EGF-receptor 
on the endosome fusion stimulated by Rin1. Rin1 is a guanine nucleotide exchange factor 
for Rab5 that supports endosome fusion [Tall et al., 2001; Galvis et al., 2009]. As shown 
in Figure 23, Rin1 stimulated endosome fusion. As expected, the addition of AG9 did not 
affect the endosome fusion. However, AG1478 inhibitor partially blocked endosome 
fusion stimulated by Rin1. Collectively, these results reinforce the conclusion that 
tyrosine kinase activity of EGF-receptor may be involved in the activation of Rab5, at 
least in part, via Rin1. 
2.5 Discussion 
Given the importance of tyrosine phosphorylation, which is produced upon 
stimulation with growth factors in intact cells, specific and selective inhibitors of tyrosine 
kinase activity are an important means for investigating receptor tyrosine kinases (i.e., 
EGF-receptor) [Citri & Yarden, 2006]. Therefore, the utilization of these inhibitors may 
be critical for elucidation of the role that tyrosine kinases play in membrane trafficking 
and signaling [Burke et al., 2001]. Furthermore, the activation of intrinsic or associated 
tyrosine kinases during the internalization of growth factor receptors is a key feature of 
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both endocytic and signaling processes. Indeed, the studies on endocytosis of kinase-
inactive mutants of several growth factors, including the EGF-receptor, suggested that 
kinase activity is necessary for maximal internalization rate, endosomal localization and 
down regulation of the receptor [Wells et al., 1999; Sorkina et al., 2002; Barbieri et al., 
2003; Wiley 2003]. 
We have shown that the addition of HNMPA-(AM)3 tyrosine kinase inhibitor blocked 
the formation of enlarged Rab5-positive endosomes upon insulin stimulation in intact 
cells expressing Rab5:wild type, but not Rab5:Q79L mutant. Consistent with this 
observation, the receptor tyrosine kinase inhibitors (i.e., AG1024) specifically block the 
fusion between early endosomes. Interestingly, the inhibitory effect was reversed by the 
addition of Rab5: Q79L mutant. These data suggest a positive role of receptor tyrosine 
kinase activity on endosome fusion that is mediated by the activation of Rab5, which is 
consistent with increase in endosome size observed upon ligand stimulation.  
The insulin receptor is a well-characterized system, which involves the internalization 
of the receptor from the plasma membrane to endosome upon ligand stimulation. In our 
experimental conditions, the binding of Biotin-insulin was saturated and nonspecific 
binding, measured in the presence of 300 fold of unlabeled Insulin, was less than 3.2 % 
of the total counts/min in the pellet. By Scatchard analysis, we determined dissociation 
constants for Biotin-insulin (Kd=0.33 nM) and for unmodified insulin (Kd=0.29 nM) in 
HepG2 cells and these values were comparable to values reported for unmodified insulin 
in the order of the nM [Backer et al., 1991; Scholz et al., 1992]. When these two 
endocytic vesicles containing Biotin-insulin and Avidin-β-Galactosidse are brought 
together upon vesicle fusion, the resulting enzymatic activity of β-galactosidase in the 
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complex, points to the specificity of the fusion reaction (Figures 5 and 6). The results 
reported here show that the fusion reaction is time, ATP and cytosol dependent with an 
optimal temperature of 37°C.  
Morphological analysis of the fusion events clearly shows that in the presence of 
cytosol the formation of endosome containing different size of gold particles. Consistent 
with these observations, fluorescence microscope analysis revealed that the accumulation 
of insulin receptor in early endosomes is dependent on tyrosine kinase activity since the 
insulin receptor is localized on the plasma membrane by the addition of the HNMPA-
(AM)3 inhibitor (Figure 10). Interestingly, we also observed that the presence of 
HNMPA-(AM)3 inhibitor blocked the formation of enlarged Rab5-positve endosomes 
(Figure 10) as well as the activation of Rab5 in intact cells (Figure 12). However, the 
addition of HNMPA-(AM)3 inhibitor neither blocked the intracellular localization of 
insulin receptor nor the formation of enlarged Rab5-positve endosomes in cells 
expressing Rab5: Q79L mutant. 
Interestingly, we also observed that the presence of AG1024 inhibitor blocked the 
activation of Rab5: wild type, but not the activation of Rab5: Q79L mutant, in intact cells 
(Figure 12). Thus, these data establish that tyrosine kinase activity of the insulin receptor 
is, in part, responsible for the formation of enlarged Rab5-positive endosomes, which is 
linked to the activation of Rab5. The potential mechanism of this inhibitory effect may be 
associated with Rin1, since it is associated with the insulin receptor upon ligand 
stimulation [Hunker et al., 2006a], and because it is also required for the fusion assay, 
whose fusogeneic activity is partially reversed by AG1024 inhibitor. These observations 
raise the possibility that the tyrosine kinase enzymatic activity of the insulin receptor may 
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be required during the fusion assay. This inhibitory effect was concentration-dependent 
and specific since AG9 (an inactive analog) did not affect the fusion reaction. More 
importantly, the presence of this inhibitory effect may be associated with an effect on the 
interaction between Rin1 and activated insulin receptor. This is in strong agreement with 
the fact that Rin1 was found significantly less associated with membrane fraction in the 
presence of HNMPA-(AM)3 upon insulin stimulation (Figure 13). However, the 
association of Rabex-5 (another Rab5 exchange factor) with membranes was not affected 
in the presence of inhibitor. These observations indicate that this inhibition by HNMPA-
(AM)3 may be selectively associated with Rin1, but not with Rabex-5. 
Because stimulation of the fusion reaction by Rin1 and Rab5, but not Rab5: Q79L 
mutant, were also partially blocked by AG1024 raises the possibility that once Rab5 is 
already activated by its exchange factor, part of this in vitro endosome fusion may be 
independent of AG1024 inhibitor. Alternatively, it is also possible that AG1024 does not 
completely block insulin receptor tyrosine kinase enzymatic activity in our in vitro 
system, which, in part, may also contribute the inability of the AG1024 to fully block the 
fusion reaction. Nevertheless, our in vitro and in vivo data support that the tyrosine kinase 
enzymatic activity of the insulin-receptor is required during the endosome fusion assay. 
On the other hand, we have also demonstrated that AG1478, an EGF-receptor 
tyrosine kinase inhibitor, blocked the fusion between endosomes. This inhibitory effect 
was reversed by the addition of Rab5:Q79L mutant, but not by the addition of Rab5:WT. 
Consistent with this observation, AG1478 blocked the formation of enlarged Rab5-
positive endosomes upon EGF stimulation in intact cells. This observation is further 
supported by the significant reduction in the perimeter of Rab5-positive endosomes 
58 
 
(Figure 17). Thus, these data suggest a positive role of receptor tyrosine kinase activity 
on endosome fusion that is mediated by the activation of Rab5, which is in agreement 
with an increase in early endosome size observed upon EGF stimulation. Interestingly, 
we also observed that the presence of AG1478 inhibitor blocked the activation of Rab5 in 
intact cells expressing Rab5:WT (Figure 18). However, the addition of AG1478 inhibitor 
neither blocked the intracellular localization of EGF-receptor nor the formation of 
enlarged Rab5-positve endosomes in cells expressing Rab5:Q79L mutant (Figure 15). 
These results are supported by the observation that the perimeter of Rab5-positive 
endosomes in cells expressing Rab5:Q79L mutant were not significantly affected by the 
addition of either EGF or AG418 inhibitor (Figure 17). Thus, these data establish that 
tyrosine kinase activity of the EGF-receptor is required for the formation of enlarged 
Rab5-positive endosomes, and more importantly, they also demonstrate that the 
inhibition of the tyrosine kinase activity of the EGF-receptor is linked to the inactivation 
of Rab5. Fluorescence microscopy analysis also revealed that the accumulation of EGF-
receptor in early endosomes is dependent on tyrosine kinase activity, since AG1478 
inhibitor also blocked the internalization of the EGF-receptor (compare Figure 14E and 
H). 
Similarly, it has been demonstrated that PD158780, another EGF receptor tyrosine 
kinase inhibitor, also affected early steps of internalization [Sorkina et al., 2002; Wolf et 
al., 2011]. Thus, it is possible that these inhibitors may work at different steps during 
endocytosis of EGF-receptor by affecting the recruitment of selective factors [Thomas et 
al., 2003; Kondratov et al., 2010]. PD158780 prevented the targeting of EGF-receptor 
into coated pits by altering the recruitment of subunits of the AP2 complex [Sorkina et 
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al., 2002]. However, here we showed that Rin1, a Rab5-GEF, was not recruited to the 
membrane upon EGF stimulation in the presence of AG1478. The possible mechanism of 
this inhibitory effect may be associated with the fact that Rin1 is associated with EGF-
receptor upon ligand stimulation [Barbieri et al., 2003], and since Rin1 is also required 
for the fusion assay [Tall et al., 2001; Galvis et al., 2009], it raises the possibility that the 
tyrosine enzymatic activity of the EGF-receptor may be required during the fusion assay. 
To our surprise, we found that the addition of AG1478 inhibitor blocked the fusion 
reaction. This inhibitory effect was concentration-dependent and specific, since an 
inactive analog (i.e., AG9) did not affect the fusion reaction. More importantly, 
stimulation of the fusion reaction by Rin1 was also partially blocked by AG1478, 
suggesting that the presence of AG1478 may affect the recruitment of Rin1 to membrane, 
which is in strong agreement with the fact that Rin1 was found to be significantly less 
associated with membrane fraction in the presence of AG1478 upon EGF stimulation. 
Consistent with this idea, we also found that Rab5:WT partially reversed the inhibitory 
effect of AG1478. Alternatively, it is possible that Rin1 may also activate Rab5 
independently of its association with the activated EGF-receptor in our in vitro endosome 
fusion system. Therefore, once Rab5 is activated, it will increase the endosome fusion 
independently of the presence AG1478 inhibitor, which is consistent with the observation 
that Rin1 activates Rab5 in an in vitro system [Tall et al., 2001]. In support of this idea, 
the addition of AG1478 neither affects the endosome fusion stimulated by Rab5:Q79L 
mutant nor the formation of enlarged Rab5:Q79L mutant-positive endosomes in intact 
cells. Nevertheless, our in vitro and in vivo data support the idea that the tyrosine kinase 
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enzymatic activity of the EGF-receptor, at least in part, is required during the fusion 
assay. 
Another view of the fusion reaction between endosomes containing Biotin-insulin or 
Biotin-EGF and Avidin-β-Galactosidase is that AG1024 inhibitor may affect the 
activation of Rab5 in one set of endosomes containing insulin receptor (i.e., Biotin-
insulin or Biotin-EGF endosomes) but not in the other set of endosomes containing 
Avidin-β-Galactosidase, a fluid phase marker. Therefore, this model predicts that Rab5 
should be present and active in both sets of endosomes during the fusion reaction. Our 
results are in strong agreement with previous observations that Rab5 was required for the 
fusion in both endosomes [Barbieri et al., 1998]. However, we have found that Rab5 is 
activated during the enodocytosis of several fluid phase markers (i.e., HRP and β-
Galactosidase). Specifically, we observed that activation of Rab5 during the uptake of 
fluid phase marker is less robust (~10%) as compared with the activation of Rab5 during 
either EGF or insulin stimulation (Figures 24 & 25), which may help to explain, in part, 
the fact that this endosome fusion is not completely inhibited in the presence of a tyrosine 
kinase inhibitor (Figure 5). These observations are consistent with previous observations 
where Rab5 was localized in endosomes containing HRP as a fluid phase marker markers 
[Gruenberg & Howell, 1986; Chavrier et al., 1990; Mu et al., 1995; Singh et al., 2003; 
Hunker at al., 2006; Zhu et al., 2007; Zhu et al., 2009]. Interestingly, it has also been 
recently demonstrated that active Rab5 was found on macropinosomes [Feliciano, et al., 
2011]. Thus, it is possible that several mechanisms of activation of Rab5 are taking place 
during receptor-mediated endocytosis and endosome fusion. For instance, dependent on 
cell type [Han & Colicelli, 1995], overexpression of Rabex-5 induces the formation of 
61 
 
enlarged endosome [Horiuchi et al., 1997; Zhu et al., 2009], but not the overexpression of 
either Rin1 [Semerdjieva et al., 2008] or RAP6 in mammalian cells; Rin1 requires 
tyrosine phosphorylation of the EGF-receptor [31], while Rabex-5 requires ubiquitination 
[Mattera et al., 2006; Penengo et al., 2006] and RAP6 does not interact with EGF-
receptor directly [Su et al., 2007]. These Rab5-GEFs were also required in several in 
vitro endosome fusion reactions [Horiuchi et al., 1997; Tall et al., 2001; Hunker et al., 
2006]. Thus, it is possible that several mechanisms of activation of Rab5 are taking place 
during EGF-receptor endocytosis and endosome fusion. Given the importance of tyrosine 
phosphorylation in signaling and endocytosis by hormones and growth factors, specific 
and selective inhibitors of tyrosine kinase activity are important means for investigating 
receptor tyrosine kinases biological functions. Thus, the utilization of these inhibitors 
may be critical for elucidation of the role of tyrosine kinase activity for both in vitro and 
in vivo setting. Furthermore, the activation of intrinsic or associated tyrosine kinases 
during the internalization of growth factor receptor is a key feature of endocytosis and  
signaling processes, in which several small GTP-ases have been implicated, including 
Rab5.   
In conclusion, we have used in vivo and in vitro approaches to investigate the role of 
tyrosine phosphorylation during the fusion reaction. Specifically, we have demonstrated 
that tyrosine kinase inhibitors affect in vitro endosome fusion, the formation of enlarged 
Rab5-positive endosomes and activation of Rab5 in intact cells. These data suggest that 
the receptor kinase activity may provide a link between early endosomes and signaling 
molecules, which in turn, will activate the small GTPase Rab5 as well as directly increase 
the fusion activity.  
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Figure 5. Effect of insulin receptor kinase inhibitor on fusion between endosomes. 
(A) Effect of cytosol and energy on the endosome-endosome fusion. Five-min vesicles 
containing either Biotin-Insulin (B-Ins) or Avidin-β-Galactosidase (Av-GAL) were 
mixed in fusion buffer supplemented with different amount of cytosol containing ATP-
regenerated (●) or ATP depleted systems (■). Samples were then transferred to 37ºC for 
the indicated times and processed as described in Material and Methods to determine the 
percentage forming the immune complex formation. The data are presented as means ± 
SD of four independent experiments. (B) Fusion assay was performed under standard 
conditions as described above either in the absence (□) or in the presence of different 
amounts of AG9 (○) and AG102 4 (●) containing 1 mg/ml of cytosol. The data are 
presented as means ± SD of four independent experiments. 
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Figure 6. Fusion between endosomes. (A) Effect of time on the endosome-endosome 
fusion. Two sets of vesicles prepared from cells that have been allowed to endocytose B-
Ins and Av-GAL for 5 min at 37ºC, respectively. Then the vesicles were mixed in fusion 
buffer supplemented with different amounts of cytosolic proteins /ml containing ATP-
regenerated (●) or ATP-depleted systems (■). Samples were then  transferred to 37ºC for 
the indicated times and processed as described in Material and Methods to determine the 
percentage immune complex formation. The data are presented as means ± SD of four 
independent experiments. (B) Av-GAL was internalized by a 3-min uptake at 37ºC and 
chased for 0, 3, 6, 12 min. Cells were then incubated at 4ºC for 1 h with B-Ins. 
Endocytosis of Insulin was induced by incubation at 37ºC and the amount of B-Ins 
associated with Av-GAL was quantitated at each time by solubilizing the cells in the 
presence of excess of biotin-BSA. Results are expressed as fluorescence units, which 
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indicates the percentage of the immune complex formed after solubilization of vesicles in 
the absence of biotin-BSA. (C) Vesicles fractions were obtained and resuspended in 
homogenization and treated as following: Antibodies: 200 ng/ml control IgG, or anti-
Rab4, anti-Rab5, or anti-EEA1, or anti-Rab11, or anti-Rin1 antibodies were added to 
fusion reaction; GDI proteins: vesicles were incubated in the presence of 1 uM GDI, 
washed and then resuspended in fusion buffer; Rab5 proteins: 0.3 μg/ml Rab5-REP-1 
complex was added to the fusion reaction; Rin1 proteins: 0.2 μg/ml of Rin1 was added to 
the fusion reaction; NEM treatment: Cytosol and vesicles were pretreated with 0.75 mM 
NEM at 4ºC for 45 min and excess of NEM was inactivated by 2 mM DTT. Fusion was 
carried out in the presence of ATPregenerating system, and the ATP-dependent fusion 
was expressed as a fraction of the fusion obtained with non-treated vesicles resuspended 
in 1.5 mg of normal cytsosol/ml for 45 min at 37ºC. Background was measured by 
incubation for 45 min at 4ºC. The data are presented as means ± SD of three independent 
experiments.  
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Figure 7. Morphology of in vitro fusion between endosomes. Sub-cellular fractions 
containing colloidal gold of 10 nm (B-Ins) and 20 nm (Av-GAL) loaded in 5-min early 
endosomes were incubated in vitro for 45 min in fusion buffer in the presence of 1.2 mg 
of cytosolic protein/ml at 37ºC (A) and at 4ºC (B). (C) Fuison was also supplemented by 
20 μM AG1024 kinase inhibitor in the presence of 1.2 mg of cytosolic protein/ml at 
37ºC. After the fusion, the samples were fixed in suspension, pelleted, and analyzed for 
transmission electron microscopy. Bars: 100 nm. (D) For each time of the fusion reaction, 
the presence of either 10 or 20 nm gold particles was assessed for at least 2,000 
endosomes under four  different experimental conditions (-ATP/37ºC, lane 1; 
+ATP/37ºC, lane 2; +ATP/37ºC in the presence of 20 μM AG1024 (KI), lane 3; 
+ATP/4ºC, lane 4). Results are expressed as a percentage of the total endosomes that 
contained 10nm and 20nm gold. Values are means of +/- SD, n = 3. 
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Figure 8. Selective effect of insulin receptor kinase inhibitor on the fusion reaction. 
The fusion assay was performed under standard conditions as described in Figure 6, 
either in the absence or in the presence of Rab5:WT or Rab5:Q79L mutant, supplemented 
with either 20 μM AG1024 or ATP in the presence of 0.5 mg/ml cytosol. The data are 
presented as means ± SD of four independent experiments. 
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Figure 9. Insulin receptor kinase inhibitor blocks endosome fusion stimulated by 
Rin1. The fusion assay was performed under standard conditions as described in Figure 
6, either in the absence or in the presence of different concentrations of Rin1 
supplemented with several concentrations of AG1024 (○: no addition, ●: 20 μM) 
inhibitor in the presence of 0.5 mg/ml cytosol. The data are presented as means ± SD of 
four independent experiments. 
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Figure 10. Confocal immunofluorescence analysis of cells co-expressing Insulin 
receptor, Rab5: wild-type in the presence of insulin receptor tyrosine kinase 
inhibitor. NIH-IR cells were transfected with plasmids encoding GFP-Rab5: wild type 
(A-L) in the absence (A-C; G-I) or in the presence of 100 ng/ml insulin (D-F; J-L). Cells 
were also supplemented with 100 μM HNMPA-(AM)3 inhibitors (G-L) and inactive 
analog (AG9) (A-F). 100 ng/ml insulin was bound to the cells at 4°C for 60 min. The 
cells were then washed with ice-cold PBS and then incubated at 37°C for 8 min. 
Subsequently, the cells were washed three times with ice-cold PBS and fixed with 4% 
paraformaldehyde and then were permeabilized with 0.1% Triton X-I00 prior to 
incubation with antibodies. The primary antibodies used were rabbit anti-insulin receptor. 
The secondary antibodies used were Alexa564-labelled donkey anti-rabbit IgG 
antibodies. Yellow color indicates areas of co-localization between the internalized 
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insulin receptor and the overexpressed GFP-Rab5 proteins (C, F, I and L). An inactive 
analog (AG9) was used as control. The optical sections viewed are 0.4 μm. Size bars, 10 
μm. 
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Figure 11. Confocal immunofluorescence analysis of cells co-expressing Insulin 
receptor, Rab5: Q79L mutant in the presence of insulin receptor tyrosine kinase 
inhibitor. NIH-IR cells were transfected with plasmids encoding GFP-Rab5: Q79L (A-
L) and in the absence (A-C and G-I) or in the presence of insulin (D-F and J-L). Cells 
were also supplemented with 100 μM HNMPA-(AM)3 inhibitors (G-L) and inactive 
analog (AG9) (A-F). 100 ng/ml insulin was bound to cells at 4°C for 60 min. Cells were 
washed with ice-cold PBS and then incubated at 37°C for 8 min. Subsequently, the cells 
were washed three times with ice-cold PBS and fixed with 4% paraformaldehyde and 
then permeabilized with 0.1% Triton X-I00 prior to incubation with antibodies. The 
primary antibodies used were rabbit anti-insulin receptor. The secondary antibodies used 
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were Alexa564-labelled donkey anti-rabbit IgG antibodies. Yellow color indicates areas 
of colocalization between the internalized insulin receptor and the overexpressed GFP-
Rab5 proteins (C, F, I and L). An inactive analog (AG9) was used as control. The optical 
sections viewed are 0.4 μm. Size bars, 10 μm. 
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Figure 12. Insulin receptor tyrosine kinase inhibitor blocks the activation of Rab5 in 
intact cells. NIH-IR were transfected with plasmids encoding GFPRab5: wild type (A) 
and GFP-Rab5: Q79L mutant (B) in the absence or in the presence of 100 ng/ml insulin 
containing either 100 μM AG9 or 100 μM HNMPA-(AM)3 (HNM) inhibitors as 
indicated in the Figure. Insulin was bound to the cells at 4°C for 60 min. The cells were 
washed and then incubated at 37°C for 8 min. Subsequently, the cells were washed three 
times with ice-cold PBS, lysed and incubated with gluthathione beads either in the 
presence of GST alone or GST-EEA1 at 4°C for 60 min. After incubation, the beads were 
washed and the presence of activated Rab5 was analyzed by Western blotting using anti-
Rab5 antibodies. The data are presented as means ± SD of four independent experiments. 
  
73 
 
 
Figure 13. Effect of HNMPA-(AM)3 inhibitor on the tyrosine phosphorylation of 
Insulin receptor and recruitment of Rin1. Cells were incubated in the absence or in the 
presence of 100 ng/ml insulin either 100 μM AG9 or 100 μM HNMPA-(AM)3 inhibitor 
as described in the Figure. After treatment, cells were washed with ice cold PBS and 
incubated at 37oC for 8 minutes. Cells were then washed again using ice-cold PBS, 
homogenized and membrane fractions were prepared as described in Materials and 
Methods. Membrane (M) and cytosol (S) fractions were treated with sample buffer and 
proteins were subject to SDS-PAGE, blotted to a nitrocellulose membrane, and 
antibodies specific to IRS-1 (A), Grb2 (B), Rin1 (B), Rabex-5 (C), tubulin, phospo-
insulin receptor (p)-IR and total (t)-IR, and tubulin were used to visualize these proteins 
by Western blot analysis. A representative experiment is shown (E). This experiment was 
repeated at least three times, and the results were reproducible. The data are presented as 
means ± SD of three independent experiments. 
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Figure 14. Confocal immunofluorescence analysis of cells co-expressing EGF-
receptor and Rab5: wild-type in the presence of EGF-receptor tyrosine kinase 
inhibitor. NR6 cells expressing either EGF-receptor wild type (A-L) or EGF-receptor 
K721M mutant (M-R) were transfected with plasmids encoding GFP-Rab5: wild type (A-
R) in the absence (A-C, G-I, M-O) or in the presence of EGF (D-F, J-L, P-R). Cells were 
also supplemented with 100 nM AG9 inactive analog (A-F) or 100 nM AG1478 
inhibitors (G-L). 100 ng/ml EGF was bound to the cells at 4°C for 60 min. Cells were 
then washed with ice-cold PBS, incubated at 37°C for 8 min, washed three times with 
ice-cold PBS, fixed with 4% (w/v) paraformaldehyde and then permeabilized with 0.1% 
(v/v) Triton X-100 prior to incubation with antibodies. The primary antibody used was 
polyclonal rabbit anti-EGF-receptor. The secondary antibody used was Alexa564-
labelled donkey anti-rabbit IgG. Yellow color indicates areas of co-localization between 
the internalized EGF-receptor (B, E, H, K, N and Q) and the overexpressed GFP-Rab5 
proteins (A, D, G, J, M and P). An inactive analog (AG9) was used as control. The 
optical sections viewed are 0.4 μm. Size bars, 10 μm. 
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Figure 15. Confocal immunofluorescence analysis of cells co-expressing EGF-
receptor, Rab5: Q79L mutant in the presence of EGF-receptor tyrosine kinase 
inhibitor. NR6 cells expressing human EGF-receptor wild type (A-L) and catalytically 
inactive mutant (K721M) (M-R) were transfected with plasmids encoding GFP-Rab5: 
Q79L (A-R) and then incubated in the absence (A-C, G-I and M-O) or in the presence of 
EGF (D-F, J-L and P-R). Cells were also supplemented with 100 nM AG1478 inhibitor 
(G-L) and 100 nM AG9 (inactive analog) (A-F). 100 ng/ml EGF was bound to the cells at 
4°C for 60 min. Cells were then washed with ice-cold PBS, incubated at 37°C for 8 min, 
washed three times with ice-cold PBS, fixed with 4% paraformaldehyde and then were 
permeabilized with 0.1% Triton X-100 prior to incubation with rabbit anti-EGF-receptor 
and Alexa564-labelled donkey anti-rabbit antibodies, respectively. Yellow color indicates 
areas of co-localization between the internalized EGF-receptor and the overexpressed 
GFP-Rab5: Q79L mutant (C, F, I, L, O and R). An inactive analog (AG9) was used as 
control. The optical sections viewed are 0.4 μm. Size bars, 10 μm. 
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Figure 16. Expression and tyrosine phosphorylation of EGF-receptor in cells 
expressing Rab5 proteins. NR6 cells expressing human EGF-receptor wild type (WT) 
and catalytically inactive mutant (K721M) were transfected with plasmids encoding 
GFP-Rab5: wild type (A) and GFP-Rab5:Q79L mutant (B) as indicate in the Figure. 
Cells were starved, stimulated or not for 8 min with EGF (100 ng/ml), and lysed in ice-
old lysis buffer as described in Material and Methods. Cell lysates were then subjected to 
SDS-PAGE and analyzed by immunoblotting using anti-phospho (p) and anti-total (t) 
EGF-receptor and anti-Rab5 antibodies. The experiment was repeated twice with similar 
results. 
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Figure 17. Effect of AG1478 on the perimeter of Rab5-positive endosomes. 
Perimeters of Rab5-positive endosomes from at least 200 cells were measured using the 
NIH Image J software from immunofluorescence images acquired using a Leica TCS SP2 
confocal microscope in NR6 cells for each experimental condition. (A-B) Histograms of 
Rab5-positive endosomes/cell vs. the endosome size were determined in NR6-E cells 
expressing Rab5 wild type (WT) alone or containing either 100 nM AG9 or 100 nM 
AG1478 in the absence or in the presence of 100 ng/ml EGF.  Asterisk (*) denotes an 
extended tail of Rab5:WT endosomes distribution in the presence of EGF. (C) 
Histograms of Rab5-positive endosomes vs. the endosome size were determined in NR6-
E cells expressing Rab5: Q79L containing either 100 nM AG9 or 100 nM AG1478 in the 
absence or in the presence of 100 ng/ml EGF. (D) Histograms of Rab5-positive 
endosomes vs. the endosome size were determined in NR6-K cells expressing Rab5: 
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Q79L in the absence or in the presence of 100 ng/ml EGF. Asterisks (**) denote an 
extended tail of Rab5: Q79L endosomes distribution in the presence of EGF. The data are 
presented as means ± SD of four independent experiments. 
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Figure 18. AG1478 inhibitor blocks the activation of Rab5 in intact cells. NR6 cells 
expressing either EGF-receptor wild type or EGF-receptor K721M mutant were 
transfected with plasmids encoding GFP-Rab5: wild type (A) and GFP-Rab5: Q79L 
mutant (B) in the absence or in the presence of EGF and 100 nM AG1478 inhibitor as 
indicated in the Figure. 100 ng/ml EGF was bound to the cells at 4°C for 60 min. The 
cells were washed and then incubated at 37°C for 8 min. Subsequently, the cells were 
washed three times with ice-cold PBS, lysed and incubated with glutathione beads either 
in the presence of GST alone or GST-EEA1 at 4°C for 60 min. After incubation, the 
beads were washed and the presence of activated Rab5 was analyzed by Western blotting. 
The data are presented as means ± SD of four independent experiments. 
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Figure 19. Effect of AG1478 inhibitor on the tyrosine phosphorylation of EGF-
receptor and recruitment of Rin1 in intact cells. NR6 cells expressing EGF-receptor 
wild type were incubated with100 ng/ml EGF and 100 nM AG1478 inhibitor as described 
in Materials and Methods. After treatment, cells were washed with ice cold PBS and 
incubated at 37oC for 8 minutes. Cells were then washed again using ice-cold PBS, 
homogenized and membrane fractions were prepared as described in Materials and 
Methods. Membrane [M] and cytosol [S] fractions (A) were treated with sample buffer 
and proteins were subject to SDS-PAGE, blotted to a nitrocellulose membrane, and 
antibodies specific to Shc (B), Grb2 (C), Rin1 (D), Rabex-5 (E), phospho(p)-EGF-
receptor, total(t)-EGF-receptor, and tubulin (A) were used to visualize these proteins by 
Western blot analysis. Relative levels of these proteins were determined by densitometry. 
Data represents the mean ± SD of four independent experiments.   
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Figure 20. Rin1 is not tyrosine phosphorylated by EGF. NR6 cells expressing human 
EGF-receptor wild type (WT) were transfected with plasmids encoding Rin1: wild type 
as indicated in the figure. Cells were serum-starved, stimulated or not for 8 min with EGF 
(100 ng/ml), lysed and then immunoprecipitated with anti-Rin1 antibodies as indicated in 
Material and Methods. The immunoprecipitates were then subjected to SDS-PAGE and 
analyzed by immunoblotting using anti-Rin1 and anti-phosphotyrosine (PY-300) 
antibodies, respectively. Whole cell lysates (WCL) were analyzed utilizing antibodies 
recognizing both total (t) and phospho (p)-EGF receptor. The experiment was repeated 
twice with similar results. 
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Figure 21. Expression of EGF-receptor catalytically inactive mutant affects the 
recruitment of Rin1 to membrane upon stimulation of EGF. NR6 cells expressing 
EGF-receptor catalytically inactive mutant (K721M) were incubated in the absence or in 
the presence of 100 ng/ml EGF at 37oC for 8 minutes as indicated in Materials and 
Methods. Cells were then washed again using ice-cold PBS, homogenized and membrane 
fractions were prepared as described in Materials and Methods. Membrane [M] and 
cytosol [S] fractions were (A) treated with sample buffer and proteins were subject to 
SDS-PAGE, blotted to a nitrocellulose membrane, and antibodies specific to Shc (B), 
Rin1 (C), Rabex-5 (D), phospho(p)-EGF-receptor and total(t)-EGF-receptor, and tubulin 
(A) were used to visualize these proteins by Western blot analysis. Relative levels of 
these proteins were determined by densitometry. Data represents the mean ± SD of three 
independent experiments.  
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Figure 22. Effect of AG1478 inhibitor on fusion between endosomes. (A) Effect of 
cytosol and energy on the endosome-endosome fusion. Five-min vesicles containing 
either Biotin (B)-EGF or Avidin (Av)-GAL were mixed in fusion buffer supplemented 
with 1 mg/ml cytosol containing an ATP-regenerating system either in the absence (○) or 
in the presence of different amounts of AG9 (□) and AG1478 (●). Samples were then 
transferred to 37ºC for the indicated times and processed as described in Materials and 
Methods in order to determine the percentage forming the immune complex formation. 
The data are presented as means ± SD of four independent experiments. (B) Fusion assay 
was performed under standard conditions as described in Figure 1A, either in the absence 
or in the presence of Rab5: wild type or Rab5: Q79L mutant, supplemented with either 20 
µM AG1478 or 0.5 mg/ml of cytosol in the presence of ATP. The data are presented as 
means ± SD of four independent experiments.  
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Figure 23. AG1478 blocks endosome fusion stimulated by Rin1. Fusion assay was 
performed under standard conditions as described in Figure 4, either in the absence or in 
the presence of different concentrations of Rin1 supplemented with 20 µM AG1478 (●) 
and 0.5 mg/ml cytosol. Empty circle (○) indicates addit ion of AG9. The data are 
presented as means ± SD of four independent experiments. 
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Figure 24. Activation of Rab5 during fluid phase and receptor-mediated 
endocytosis. NIH-IR cells were transfected with plasmids encoding GFPRab5: wild type 
in the absence or in the presence of 100 ng/ml insulin (INS), 2 mg/ml HRP and 1 µg/ml 
b-Galactosidase (GAL) as indicated in the Figure. Each ligand was incubated with cells at 
4°C for 60 min. Cells were then incubated at 37°C for 8 min. Subsequently, the cells 
were washed three times with ice-cold PBS, lysed and incubated with glutathione beads 
either in the presence of GST-EEA1 at 4°C for 60 min. After incubation, the beads were 
washed and the presence of activated Rab5 was analyzed by Western blotting using anti-
Rab5 antibodies. The data are presented as means ± SD of two independent experiments. 
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Figure 25. Activation of Rab5 during fluid phase and receptor-mediated 
endocytosis. NR6 cells expressing EGF-receptor wild type were incubated in the absence 
or in the presence of 100 ng/ml EGF and 2 mg/ml HRP as indicated in the Figure. Each 
ligand was incubated with cells at 4°C for 60 min. Cells were then incubated at 37°C for 
5 min. Subsequently, the cells were washed three times with ice-cold PBS, lysed and 
incubated with glutathione beads either in the presence of GST alone or GST-EEA1 at 
4°C for 60 min. After incubation, the beads were washed and the presence of activated 
Rab5 was analyzed by Western blotting. The data are presented as means ± SD of four 
independent experiments.  
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CHAPTER 3 
RAB5 CAN BE ACTIVATED THROUGH AT LEAST THREE DISTINCT 
ENDOCYTIC PATHWAYS 
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3.1 Abstract 
The process of endocytosis is a complex pattern of membrane vesicle trafficking, 
which permits the continuous flow of membrane between cell surface and various 
intracellular compartments, via fusion and fission events, with Rab5 mediating the fusion 
events of early endosomes.  Since it has been well established that varying concentrations 
of Epidermal Growth Factor (EGF) during the endocytosis of EGF Receptor (EGFR) can 
elicit uptake via numerous endocytic routes, we were interested in analyzing which of 
these endocytic pathways is/are responsible for activation of Rab5. Rab5 is activated in 
an EGF concentration dependent manner (from 2ng/ml to 500ng/ml), plateauing at 
100ng/ml.  It was also observed that if cells are stimulated with low quantities of EGF 
(2ng/ml), temporal activation of Rab5 peaks at about 2.5 minutes and diminishes within 
10 minutes. However, if cells are stimulated with high concentration of EGF 
(>100ng/ml), the temporal activation of Rab5 is both heightened as well as prolonged, 
where even 10 minutes after stimulation, relative activity of Rab5 is much higher than at 
the maximum point during stimulation with low concentration of EGF. Furthermore, by 
utilizing specific inhibitors against key regulators of endocytosis and by varying the 
concentration of EGF stimulation, I have provided evidence for the existence of at least 
three distinct pathways of Rab5-dependent internalization of growth factor receptors. 
However, overexpression of either Rin1 or Rabex-5 is able to rescue Rab5 activity even 
in absence of EGF and/or in the presence of any of the employed inhibitors. Taken 
together, these results constitute evidence showing selective activation of Rab5 with 
respect to the different routes of uptake of EGFR. 
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3.2 Introduction 
Cellular membranes allow for compartmentalization of cellular chemistry by 
generating precise accumulation of proteins on their surfaces or by generating diffusion 
barriers between lumina and cytoplasm. Variations in the distribution, protein and lipid 
structure, as well as the luminal makeup of the cellular membranes through the very 
dynamic fission and fusion reactions that transpire from and between such cellular 
compartments, are chief regulators of most, extra-nuclear cell biological processes. Such 
is endocytosis, a process by which cells internalize extracellular molecules, and in doing 
so control lipid and protein composition of the plasma membrane for the ultimate purpose 
of regulating cellular interaction with its environment. Depending on the type of cargo 
that is to be internalized, this can mean regulating expression of cell surface proteins, 
sampling the cell’s surroundings for development and guidance cues, transporting 
nutrients into cells, regulating the activation of signaling pathways, rescuing proteins 
placed after vesicle fusion or turning over membrane components by degradation in 
lysozymes [Doherty and McMahon, 2009; McMahon & Boucrot, 2011]. On the other 
hand, pathogens often try to exploit cell’s endocytic machinery in order to mediate their 
internalization. There are numerous routes of endocytosis mobilized by cells. Among 
others, these are Clathrin Mediated Endocytosis (CME) [Roth & Porter, 1964], Caveolin 
Mediated Endocytosis (CavME) [Rothberg et al, 1992], those independent of clathrin and 
caveolin (CLIC/GEEC type [Kirkham & Parton 2005; Mayor & Pagano, 2007], flotillin 
associated [Frick et al., 2007], macropinocytosis [Shao et al., 2002] and entosis 
[Overholtzer et al., 2007]). 
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CME, the most studied and best characterized pathway of endocytosis, proceeds 
through initiation, selection of cargo, assembly of the coat, scission and uncoating of the 
vesicle. Although the major protein which makes up the lattice-like coat around the 
vesicles, clathrin, does not directly bind to the membrane or cargo receptors, adaptor 
proteins (such as AP2) and accessory proteins (such as epsin and AP180) are recruited to 
the plasma membrane in order to form the clathrin coat, all of which are recycled for 
reuse in another cycle of endocytosis once the vesicle has formed [McMahon & Boucrot, 
2011].   
Even though the endocytosis of cargo receptors can be stimulated by ligand binding 
(as in the case of EGFR, epidermal growth factor receptor), some receptors (such as the 
transferrin receptor, TfR) are constitutively internalized [Hopkins et al., 1985]. Upon 
internalization, cargo is sorted in endosomes prior to either being recycled back to the 
cell surface, or degraded by the lysosome by fusing with the late endosome and the 
multivesicular body, (MVB) [Grant & Donaldson, 2009].  
Chlorpromazine hydrochloride is a cationic amphipathic chemical which has been 
extensively used as a potent inhibitor of the clathrin mediated pathway since it inhibits 
clathrin assembly at the plasma membrane. It should however be noted that that by doing 
so, it does not affect uptake through caveolin/lipid raft type endocytic pathways [Wang et 
al., 1993; Rejman et al., 2005]. On the other hand, since chlorpromazine is an 
amphipathic molecule, it is able to interfere with the biogenesis of large intracellular 
vesicles, such as micropinosomes, probably due to the fact that it can insert itself into the 
lipid bilayer and hence increase fluidity of the plasma membrane. This in turn can inhibit 
formation of membrane invaginations as seen during macropinocytosis. Chlorpromazine 
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has also been shown to inhibit function of Phospholipase C (PLC) which has previously 
been shown to be an important regulator of actin dynamics and therefore also 
macropinocytosis [Ogiso et al., 1981; Walenga et al., 1981; Giocondi et al., 1995; Wells 
et al., 1999; Ivanov 2008].  
Although CME has been the most widely studied pathway and the best characterized 
pathwy, recently, it has been shown that cargo can be internalized via numerous clathin 
independent pathways, also referred to as CIs or Clathrin Indepdendent pathways. 
[Mayor & Pagano, 2007]. Moreover, these CIs constitute for approximately three times 
as much volume of fluid and bulk membrane endocytosed compared to the canonical 
CME [Howes et al., 2010]. Hence, the study of CIs is becoming progressively more 
important, but also more complex because these pathways have been shown to be quite 
diverse as shown in Figure 1.  
There is a question of which GTPase is used in the scission of the vesicle from the 
cell membrane. Some CIs, such as the Caveolin Mediated pathway (CavME) require 
dynamin (just as the CME pathway), whereas others do not (Clathrin and caveolin 
independent carrier proteins, also known as CLICs). Furthemore, CLICs can be 
additionally subdivided by the involvement of various small GTPases (CDC42, RhoA or 
ARF6) in their respective endocytic pathway(s) [Qualmann & Mellor, 2006; D’Souza-
Schorey & Cavrier, 2006; Mayor & Pagano, 2007]. Although the aforementioned small 
GTPases have been experimentally shown to be involved in their respective pathways 
(via mutants), it should also be noted that this does not necessarily meant that the small 
GTPases are obligatory for that particular pathway.  
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Caveolin mediated dynamin dependent pathway is the most studied and best 
characterized CI route of entry. As previously mentioned, CavME is dependent on 
dynamin and caveolin (the coat that will form around the invagination of the soon to be 
vesicle) in areas of the membrane where there is an abundance of sphingolipids, 
cholesterol, signaling proteins and GPI-APs (glycosyl phosphatidylinositol-anchored 
proteins) [Simons & Ikonen, 1997; Parton & Simons, 2007]. CavME pathways also have 
very diverse cargo, ranging from lipids, proteins and lipid anchored proteins. To 
pathogens, however endocytosis of these cargo is not subject just to CavME, but other CI 
pathways as well, which in turn points to the redundancy of endocytic mechanisms for 
certain molecules [Mayor & Pagano, 2007]. Another dynamin dependent but clathrin 
independent pathway of endocytosis is the one regulated by the small GTPase RhoA 
which has been shown to be responsible for the internalization of the B-chain of the 
interleukin-2 receptor (IL-2R-β) as well as other proteins (such as γ-c-cytokine and IgE 
receptors) in immune cells and fibroblasts  [Lamaze et al., 2001].  
Filipin, from the polyene family of antibiotics, is a specific inhibitor of the caveolin 
mediated pathway which leaves the clathrin mediated uptake unaffected [Schnitzer et al., 
1994; Orlandi et al., 1998; Rejman et al., 2005]. It has been shown to sequester 
cholesterol from membrane structures by creating aggregates in the membrane that 
accumulate cholesterol which in turn leads to profound changes in structure and function 
of cholesterol rich membrane domains [Orlandi & Fishman 1998; Ros-Baro et al., 2001; 
Ivanov 2008]. Another very useful tool in assessing mechanism of dynamin dependent 
pathways is the specific inhibitor dynamin called dynasore [3-Hydroxy-naphthalene-2-
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carboxylic acid (3,4-dihydroxy-benzylidene)-hydrazide hydrate]. Dynasore inhibits the 
GTPase activity of dynamin1 and dynamin2 and in doing so arrests the formation of 
endocytic clathrin coated pits and vesicles, but has no effect on dynamin independent 
cellular processes [Macia et al., 2006]. Hence by utilizing a combination of 
chlorpromazine, dynasore, and filipin, in combination with siRNA against their 
respective targets, one could gain great insight into the various mechanisms of transport 
of particular cargo by the aforementioned pathways of endocytosis.   
On the other hand, cells can also utilize pathways independent of both clathrin and 
dynamin and hence also of caveolin. These CLIC pathways were first discovered by 
observing an increase in fluid-phase endocytosis when expression of dynamin was 
knocked down [Damke et al., 1995]. However, they are dependent on one of the two 
small GTPases, either CDC42 or ARF6 from the Rho and Arf family of GTPases 
respectively. Furthermore, it has been well established that these CLIC pathways, in 
addition to being independent of dynamin are enriched in GPI-anchoring proteins, 
sensitive to cholesterol depletion, and contribute a significant fraction of CTxB (Cholera 
Toxini subunit B), ricin and fluid internalization [Sabharanjak et al., 2002; Kirkham et 
al., 2005; Chadda et al., 2007; Kumari & Mayor, 2008; Howes et al., 2010]. 
Endocytosis of the Epidermal Growth Factor Receptor (EGFR) is one of the most 
well characterized models for studying the morphology, kinetics and mechanisms of 
endocytic pathways, and is a prototypic model for the endocytosis of other Receptor 
Tyrosine Kinases (RTKs) (Figure 27). The first comprehensive study on EGF 
endocytosis was described by Carpenter and Cohen [1976], in which many of the key 
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concepts of internalization and lysosomal degradation of EGF have been established, 
which still remains as the foundation of our current understanding of EGFR endocytosis. 
EGFR is also the most popular model used to study the interplay between endocytosis 
and signaling. After internalization, EGF and EGFR are efficiently degraded, leading to a 
significant decrease in the half-life of the EGFR protein [Stonscheck & Carpenter, 1984], 
while accelerated internalization and degradation of activated EGFR leads to EGF-
induced down regulation of EGFR. Therefore, control of intensity and duration of 
receptor signaling is mainly regulated via the negative feedback regulatory mechanism of 
EGFR [Wells et al., 1990]. Basal turnover rates of non-stimulated EGFR reciprocally 
correlate with their expression levels. This is most likely due to the saturation of the 
internalization and degradation steps of trafficking. Furthermore, it has also been shown 
that the binding of EGF to EGFR results in acceleration of receptor internalization. This 
is due to the internalization of EGFR complexes through clathrin coated pits [Wiley et al., 
1991] because overexpression of dominant-negative mutants as well as RNA interference 
proteins essential for CME inhibited EGFR internalization [Damke et al., 1995; Motley et 
al., 2003; Huang et al., 2004; Sorkin & Goh, 2008]. Hence, both lines of evidence 
strongly argue that CME is the major pathway of EGFR internalization.  
Interestingly, high internalization rates of EGFR, that are characteristic of CME, were 
observed only when EGF was used in low, physiological concentrations (≥1–2 ng/ml), 
whereas the apparent rate of EGF uptake was decreased with increasing EGF 
concentrations. Based on such a saturation of the internalization process, the Wiley et al. 
proposed that the presence of high concentrations of EGF-receptor complex at the cell 
surface limits the capacity and overwhelms the rapid internalization pathway [Wiley, 
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1988; Lund et al., 1990]. More recently, it was shown that the internalization of high 
EGF concentrations was only minimally affected by overexpression of the dominant 
negative dynamin mutant or by knockdown of clathrin heavy chain by siRNA, both of 
which have been previously shown to significantly impede the CME pathway at low 
concentrations of EGF [Jiang & Sorkin, 2003; Sigismund et al., 2005]. Hence, under 
physiological conditions (low ligand concentrations and moderate expression levels of 
EGFR), EGFR is internalized mostly by CME, whereas under conditions of receptor 
overexpression and/or high ligand concentrations, the CIs determine(s) the uptake of 
EGFR into the cell [Sorkin & Goh, 2008].   
In addition to CME, in cells where EGFR activation leads to increased membrane 
dynamics, ruffling and pinocytosis, EGFR complexes can enter the pinocytic vesicles and 
ruffle-generated endocytic compartments. However, in other cells, activated EGFR can 
be taken up by the mechanisms sensitive to cholesterol-disrupting drugs as well as 
through CavME pathways. Although they may have faster kinetics as compared to the 
constitutive receptor internalization, all these CI pathways are significantly slower than 
CME.  
The lack of specific inhibitors of clathrin-independent endocytosis makes it 
problematic to explain the mechanisms and assess the significance of these pathways in 
EGFR internalization [Sorkin & Goh, 2008]. Previous studies have also shown that 
overexpression of Rab5 enhances EGF-stimulated endocytosis of EGFR, whereas the 
dominant negative form of Rab5 (S34N) represses these processes [Barbieri et al., 2000; 
Dinneen & Ceresa 2004]. Furthermore, Rab5: S34N substantially inhibits degradation of 
EGFR, whereas continual expression of Rab5: Q79L (the constitutively active form) 
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causes a ligand-independent internalization of EGFR into intracellular vesicles [Barbieri 
et al., 2004; Chen et al., 2009].  
 
Here, I have taken advantage of the well-characterized trafficking pathways of the 
EGF receptor, in order to assay the differential activation of Rab5. We show that if cells 
are stimulated with low quantities of EGF [2ng/ml], temporal activation of Rab5 peaks at 
about 2.5 minutes and diminishes within 10 minutes. However, when cells are stimulated 
with high concentrations of EGF [>100ng/ml], the temporal activation of Rab5 is both 
heightened as well as prolonged, where even 10 minutes after stimulation, relative 
activity of Rab5 is much higher than at the maximum point during stimulation with low 
concentration of EGF. Furthermore, by utilizing specific inhibitors against key regulators 
of endocytosis (Dynasore hydrate, Chlorpromazine hydrochloride and Filipin) and by 
varying the concentration of EGF stimulation, we have provided first evidence for the 
existence of at least three distinct pathways of Rab5-dependent internalization of growth 
factor receptors. However, overexpression of either Rin1 or Rabex-5 is able to rescue 
Rab5 activity even in absence of EGF and/or in the presence of any of the employed 
inhibitors. Taken together, these results constitute evidence showing selective activation 
of Rab5 with respect to the different routes of uptake of EGFR as well as differential 
activation of Rab5 by three Rabex-5 isoforms. 
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3.3 Materials & Methods 
 
3.3.1 Cell Culture & Materials  
NR6 cell line overexpressing the human EGF receptor (NR6-E) was grown to 
confluence in Dulbecco’s modified Eagle’s medium supplemented with 5% fetal bovine 
serum and 200ug/ml G418. Rab5, Rabex-5, α-Tubulin and phospho-EGFR antibodies 
were from Cell Signaling Technology (Beverly, MA). Rin1 antibody was purchased from 
Abcam Inc and total EGFR antibody was from Santa Cruz Biotechnology Inc (Santa 
Cruz, CA). EGF was purchased from Merk KGaA (Darmstadt, Germany). All HRP 
labeled secondary antibodies were purchased from Jackson ImmunoResearch 
Laboratories (West Grove, PA) while all Alexa-conjugated secondary antibodies were 
purchased from Life Technologies (Grand Island, NY). Chlorpromazine, dynasore 
hydrate and filipin were obtained from Sigma (St. Louis, MO). All other chemicals were 
obtained from Sigma, unless otherwise stated. 
3.3.2 Assessment of Rab5 activity via EEA1 pulldown assay  
NR6-E cells were lysed using a buffer containing 20 mM HEPES (pH 7.5), 100 mM 
NaCl, 1 mM DTT, 5 mM MgCl2, 5% glycerol and 1% Triton-X-100 supplemented with 1 
mM PMSF. Lysates (0.5 ml) were then incubated with 50 μl glutathione beads containing 
~5  μg o f GST-EEA1 at 4ºC while rocking for 1 hr. After incubation, the beads were 
washed three times using the lysis buffer. The pull-downs were subjected to SDS-PAGE 
and analyzed by immunoblotting using an anti-Rab5 antibody. 
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3.3.3 Subcellular Fractionation 
NR6-E cells were cultured in 100cm2 dishes until confluency and then serum starved 
for 14hrs. After starvation, cells were washed with PBS once, then allowed to bind 
100ng/ml EGF for 1hr at 4oC after which they the uptake was done at 37oC for 5min. 
They were then washed again with PBS to remove any unbound ligand and resuspended 
in binding buffer (PBS, 1mM PMSF, 1mM EDTA, 1mM EGTA, 1mM NaF, 1mM 
Na3VO4 and 1mM DTT) and lysed by passing through a homogenizer 15 times. The 
homogenate was centrifuged at 600 x g to pre-clear cell and nuclear debris and then at 
75,000 x g for 1hr at 4oC to separate the cytosol and membrane fractions. Membrane and 
cytosol fractions were then treated with sample buffer and subject to subsequent western 
blotting. 
3.3.4 Western Blot analysis  
NR6-E cells were cultured in a 6-well plate in growth medium and then serum-
starved for 14 hrs. After starvation, cells were washed with PBS and then allowed to bind 
EGF for 1hr at 4oC and then after which the uptake was done at 37oC for the noted time. 
Cells were then lysed in ice-cold lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl 
and 1% Triton x-100). The lysates were clarified by centrifugation and subjected to SDS-
PAGE and analyzed by Western blotting using the specific antibodies. Relative Units of 
proteins were determined by densitometry using the ratio of Rab5, phospho-EGFR, Rin1, 
or Rabex-5 to total-EGF-receptor and tubulin, respectively. 
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3.3.5 Inhibition of endocytosis  
NR6-E cells were cultured in a 6-well plate in growth media and then serum-starved 
for 14hrs. After starvation, cells were treated with either 20 µM chlorpromazine, 80 µM 
dynasore hydrate, 1mg/ml filipin, or a combination of the three, for 30 minutes at 4oC. 
EGF was then allowed to bind EGF for 1hr at 4oC and then after which the uptake was 
done at 37oC for 2.5 minutes, after which the cells were then lysed in ice-cold lysis 
buffer. The lysates were clarified by centrifugation and subjected to SDS-PAGE and 
analyzed by Western blotting using the specific antibodies.  
3.3.6 Confocal microscopy  
NR6-E cells were seeded on glass coverslips at 1.0 × 105 per well. The following day, 
cells were transfected using FugeneHD with either pEGFP-Rab5: WT. Cells were then 
starved in serum-free Dulbecco's modified Eagle's medium supplemented with 5% BSA 
Fraction V (MP) the next day overnight, and treated as indicated with 20 µM 
chlorpromazine, 80 µM dynasore hydrate, 1mg/ml filipin, or a combination of the three, 
for 30 minutes at 4oC, after which they were treated with either 2ng/ml or 100 ng/ml EGF 
for 1hr at 4oC and then stimulated to take up the ligand for 2.5 min at 37oC. They were 
washed with PBS and fixed in 4% paraformaldehyde for 20 minutes. Fixed cells were 
permeabilized using 0.1% Triton X-100 for 20min at room temperature and subsequently 
probed either with the rabbit polyclonal EGF-receptor or Rabex-5 antibodies for 1hr. 
Secondary antibody used was Alexa594-conjugated goat anti-rabbit IgG. Coverslips were 
mounted with Prolong and viewed on a Leica TCS SP2 confocal microscope. 
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3.3.7 Image analysis 
Images of fluorescent Rab5-positive endosomes were obtained using Leica TCS 
software. Endosome size distribution of at least 1252 Rab5wt endosomes from NR6-E 
cells alone or NR6-E cells overexpressing Rabex-5 constructs (Full length, Long or 
Short) were analyzed by measuring both endosome diameter and perimeter using NIH 
Image J software (obtained from http://rsweb.nih.gov/ij/). 
3.3.8 siRNA knockdown of Caveolin, Dynamin, Rin1 and Rabex-5  
In a 6-well dish, 1-1.5x105 cells were plated per well and transfected with 50pmol of 
siRNA when cells reached 40-50% confluency. The sequences of mouse siRNA used 
were the following: Caveolin1- 5’GGCCAGCUUCACCACCUUCUU3’; Dynamin1-
5’GGAUUUGGCCAACUCUGAU3’; Dynamin2- 5’UUAACCACGCCGAUAUAGC3’; 
Rabex5- 5’GCUCCCAGUCCUUCCAUAA3’; Rin1 siRNA was purchased as a pool of 
three specific 20-25nt long siRNAs from Santa Cruz Biotechnology, Inc. (sc-40912). 
3.4 Results 
3.4.1 Activation of Rab5 is dependent on temperature, concentration of ligand and 
time. 
 
To optimize conditions for activation of Rab5, NR6 cells over-expressing EGFR 
(NR6-E cells) were allowed to bind various concentrations of EGF (0, 2, 50, 100 or 
500ng/ml) for one hour at 4oC, after which they were stimulated to internalize the 
receptor-ligand complex at 37oC for 5 minutes (previously described by Lenhard et al., 
1992, as optimal conditions for endosome-endosome fusion) and assayed for activation of 
Rab5. Because it has already been established that EGFR can be endocytosed via 
different pathways, depending on the concentration of ligand used, we decided to 
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examine activation of Rab5 using various concentrations of EGF. We saw that there was 
a concentration dependent activation of Rab5 with respect to the amount of EGF 
employed, which plateaued at 100ng/ml (Figure 27). Because a difference in activation at 
Low concentration (2ng/ml), in comparison to High concentration (100ng/ml) was 
observed, activation of Rab5 was then tested at different time points using both Low and 
High concentrations of EGF using a similar protocol, where we observed activation of 
Rab5 after 0, 1, 2.5, 5, 10 and 20 minutes of EGFR uptake. Using Low concentration of 
EGF, when the clathrin dependent endocytosis of EGFR is predominantly utilized, we see 
that the optimal Rab5 activation is around 2.5 minutes after stimulation at 37oC, where it 
plateaus until 5min and then starts to decrease until 10 minutes after stimulation, when do 
not detect any active Rab5 (Figure 28a & 28b). On the other hand, when using High 
EGF, or when clathrin independent uptake of EGFR is predominant, both a heightened as 
well as prolonged activation of Rab5 was observed in comparison to Low EGF. Upon 
EGFR uptake, Rab5 activation peaked approximately after 5 minutes of uptake and 
started to decrease but remained partially detectable after 10 minutes and was 
undetectable after 20 minutes of uptake (Figure 28a & 28b).  When looking at the 
phosphorylation of EGFR, the same trend was observed, where Rab5 activation was 
highly correlated to EGFR phosphorylation. However, some EGFR phosphorylation was 
detected even 20 minutes after uptake (Figure 28c).  This is in agreement with the 
previous results which associate the tyrosine kinase activity of receptors to activation of 
Rab5 [Jozic et al., 2011; Jozic et al., 2012]. We then went on to optimize the temperature 
at which Rab5 activation is ideal. Using low EGF, we observed inhibition of Rab5 
activity at both 4oC and 17oC, while no effect at 37oC (Figure 29). This is in agreement 
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with current understanding of endosome fusion, since at 4oC both receptor internalization 
and endosome fusion are blocked, while at 17oC only endosome fusion is blocked and at 
37oC both internalization or fusion are intact. 
3.4.2 Rab5 can be activated via at least three distinct pathways of EGFR endocytosis. 
 
Rab5 was differentiatlly activated by low and high concentrations of EGF suggesting 
that different pathways of activation might be involved. First, NR6-E cells were treated 
with Chlorpromazine, a specific inhibitor of clathrin (and therefore clathrin mediated 
endocytosis (CME)), and then stimulated with low or hight EGF to measure Rab5 
activation. A significant inhibition of Rab5 activation at low EGF was observed when 
utilizing the specific inhibitor of CME Chlorpromazine (Figure 30a) which is in 
accordance to the literature. However, a very minute decrease in activation at high EGF 
was observed when using Chlorpromazine (Figure 30a), which points to the fact that at 
low EGF Rab5 is predominantly activated through the CME pathway, but at high EGF, 
Rab5 can be activated in pathway(s) independent of CME. Specific inhibitors of clathrin 
independent pathways were then used to better ascertain the contribution of Rab5 
activation. Since Filipin is a specific inhibitor of caveolin which does not inhibit or 
interact with clathrin, when Filipin was utilized in our system, it caused a major reduction 
of Rab5 activation at high concentration of EGF (attributed to activation of Rab5 via 
CavME), but no effect at low EGF (Figure 30b & 31). Since both the caveolin and 
clathrin mediated pathways can be controlled by dynamin, an inhibitor of dynamin called 
Dynasore hydrate was employed, and which showed a similar inhibition to 
Chlorpromazine at low EGF and a more pronounced effect in comparison to Filipin at 
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high EGF (Figure 30c & 31), meaning that there is/are pathway(s) of EGFR uptake 
independent of CME and CME which can activate Rab5. Because there are no specific 
inhibitors of other CIs available, other aspects to Rab5 activation could not be further 
delineated, which altogether points to at least two specific pathways of Rab5 activation 
and one CI pathway which is independent of dynamin.   
Morphology of NR6-E cells indicates a similar story. NR6-E cells were transfected 
with GFP-Rab5 and treated the cells as described above, but instead of lysing them and 
using for EEA1 pull-downs, the cells were fixed with paraformaldehyde and examined 
with anti-EGFR antibodies.  In comparison to cells which have not been stimulated with 
EGF, where Rab5 is localized in very punctuate structures that do not localize with 
EGFR (Figure 32: A1-A3), if cells are stimulated with either low EGF (Figure 32: B1-
B3) or high EGF (Figure 32: C1-C3) but without any inhibitor, formation of enlarged 
Rab5 positive endosomes and co-localization with EGFR were observed (Figures 32: B1-
C3). However, if Chlorpromazine at low EGF was utilized, a reduction in the number of 
Rab5 positive endosomes as well as the co-localization with EGFR (Figure 32: D1-D3) 
was observed, but when high EGF is employed, more internalized EGFR, more co-
localization with Rab5 and more enlarged Rab5-positive endosomes were observed 
(Figures 32: E1-E3). Filipin at Low EGF does not seem to inhibit EGFR internalization, 
its localization with Rab5 or the formation of Rab5 positive endosomes (Figures 32: H1-
H3), whereas at High EGF, it decreases the amount of enlarged Rab5-positive endosomes 
as well as the co-localization of EGFR with Rab5 (Figures 32: I1-I3).   
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Utilization of Dynasore seems to have the most effect on both internalization of 
EGFR as well as the formation of Rab5 positive endosomes and co-localization of EGFR 
with Rab5 at both Low and High EGF (Figures 32: F1-G3).  If we combine 
Chlorpromazine and Dynasore, we almost completely inhibit both the formation of 
enlarged Rab5 positive endosomes as well as the internalization of EGFR was inhibited 
at low EGF (Figures 32: J1-J3), but not at high EGF (Figures 32: K1-K3). Lastly, if 
Dynasore and Filipin were used, there is an apparent decrease in amount of enlarged 
Rab5-positive endosomes and some inhibition of EGFR internalization at Low EGF 
(Figures 32: L1-L3), and a less pronounced inhibition at High EGF (Figures 32: M1-M3), 
meaning that apart from dynamin mediated CME and CavME, there appear to be other 
pathways through which Rab5 can mediate endosome-endosome fusion, i.e., enlarged 
Rab5-positive endosomes.  
3.4.3 Rabex-5 and Rin1 can both rescue activation of Rab5 when one of the pathways 
of EGFR internalization is blocked. 
 
Since several pathways of Rab5 activation were established above, the focus of 
interest switched to understand what was happening to Rab5 GEFs Rabex-5 and Rin1, 
namely if they had selective effects on specific pathways of EGFR endocytosis. If either 
Rin1 or Rabex-5 were overexpressed, no matter which pathway we try to inhibit, 
activation of Rab5 was rescued (Figure 33). On the other hand, if Rabex-5 is knocked 
down using siRNA, no detectable Rab5:GTP  was observed when stimulated by either 
low or high EGF (Figure 34), meaning that Rabex-5 must play an essential role in 
activation of Rab5, regardless which pathway of EGFR endocytosis is employed.   
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3.4.4 Rabex-5 splice variants selectively activate Rab5. 
Because Rabex-5 knockdown has a debilitating effect on activation or Rab5 and since 
there are three naturally occurring splice variants of Rabex-5, the ability to selectively of 
these three splice variants to selectively activate Rab5 was examined. As shown in Figure 
35a, the splice variant which has been extensively used to characterize structure and 
function of Rabex-5 by various groups (termed here Rabex-5: Full Length or Rabex-5: 
FL).  Furthermore, our laboratory has discovered two other splice variants from human 
placenta which we have termed Rabex-5: Short (missing 31 amino acids between the 
MIU and the MBM domains and the terminal 8 amino acids of the VPS9 domain in 
comparison to Rabex-5: FL) and Rabex-5: Long (contains extra 139 amino acids at the N 
terminus as well as 38 amino acids extra in the MBM domain in comparison to Rabex-5: 
FL). 
First, each splice variant was overexpessed in NR6-E cells and activation of Rab5 
using 0, low or high EGF was examined as previously described. As shown in Figure 
35b, all three splice variants were able to activate Rab5 without stimulation by EGF, 
however, Rabex-5: Short isoform activated Rab5 somewhat less (Figure 35b). Second, 
when GFP-Rab5 was transfected into cells expressing the Rabex-5 isoforms, it was 
observed that both Long and Short splice variants do not have much of an effect at low 
EGF but they do have a significant impact on formation of Rab5-positive endosomes 
when high EGF was utilized. This is further accented by a higher Pearson coefficient of 
correlation for each condition when cells were stimulated by high EGF (Figure 36). 
Third, when the perimeter of endosomes under each condition was compared, a decrease 
in the number of cells with an enlarged endosome perimeter for Rabex-5: Short splice 
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variant in comparison to either Rabex-5: FL or Rabex-5: Long splice variants were 
observed (Figure 37). Last, subcellular distribution of Rabex-5 splice variants was 
compared upon stimulation by differing concentrations of EGF. For Rabex-5: FL and 
Rabex-5: Long splice variants, as EGF was added to the cells, Rabex-5 started to 
accumulate in the membrane fraction with High EGF attributing much more to the 
membrane fraction than low EGF (Figure 38). Alternatively, for Rabex-5: Short splice 
variant, although the distribution of membrane to cytosol at low EGF is similar to what 
was previously observed with Rabex-5: FL and Rabex-5: Long, at high EGF there is not 
as much of a shift from the cytosol to the membrane fraction (Figure 38). 
3.5 Discussion 
Endocytosis of EGFR has been a well characterized process which commences with 
ligand stimulation, proceeds with ligand-receptor complex internalization, fusion with 
early endosome and then either degradation in the lysosome or recycling back to the cell 
surface. Since it has been well established that varying concentrations of EGF during the 
endocytosis of EGFR can elicit uptake of the ligand-receptor complex via numerous 
endocytic routes [Damke et al., 1995; Jiang & Sorkin, 2003; Sorkin & Goh, 2008] and 
given that Rab5 has been termed as the master regulator of endosome biogenesis [Zerial 
& McBride, 2001; Zeigerer et al., 2012] elucidating the role of this small GTPase could 
be essential to understanding the mechanism of each of these endocytic routes. Our 
previous work has already shown that the tyrosine kinase activity of RTKs (namely 
EGFR and IR) is closely tied to activation of Rab5 in mouse fibroblast NR6 cells and 
human hepatocyte HepG2 cells respectively [Jozic et al., 2011; Jozic et al., 2012].  
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Here I show that activation of Rab5 is dependent on temperature, time and 
concentration of ligand available to the receptor at the plasma membrane which can 
directly be correlated to the tyrosine phosphorylation of EGFR. As Sorkin’s group has 
shown, although pathways which internalize high quantity of ligand/receptor may have 
faster kinetics as compared to the constitutive receptor internalization, all these CI 
pathways are significantly slower than CME [Sorkin & Goh, 2008]. Hence, it should be 
of no surprise that we were able to detect active Rab5 even 10 minutes after the uptake of 
receptors had commenced when high concentration of EGF was utilized (Figure 30b). 
Although varying the concentration of ligand elicits numerous pathways of EGFR 
endocytosis, it was previously shown that inhibition of either dynamin or clathrin (by 
overexpression of dominant negative mutants or by silencing via siRNA) can inhibit 
CME dependent uptake of EGFR (when availability of EGF is low), while having 
minimal effects on EGFR dependent endocytosis when availability of EGF is High [Jiang 
& Sorkin, 2003; Sigismund et al., 2005]. By utilizing this knowledge, I employed specific 
potent inhibitors against clathrin (chlorpromazine), dynamin (dynasore) and caveolin 
(filipin) to understand how inhibition of each pathway may affect activation of Rab5. 
What we found was that Rab5 may be activated via at least three different pathway of 
EGFR endocytosis.  
First, I confirmed that Rab5 can be activated through CME. When the availability of 
EGF at the plasma membrane is Low or when the primary pathway of EGFR endocytosis 
is through the canonical CME, inhibition of this pathway should also significantly inhibit 
activation of Rab5, which was previously observed when chlorpromazine was used to 
inhibit CME (Figure 30a). Furthermore, because the contribution of CME to endocytosis 
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of EGFR when the availability of EGF is high should be minimal, inhibition of CME 
during this time should also have minimal impact on activation of Rab5, which was 
previously observed (Figure 30a). Formation of enlarged Rab5 positive endosomes in 
intact cells (which are indicative of endosome-endosome fusion and therefore activation 
of Rab5) where utilization of chlorpromazine at Low EGF significantly retarded the 
formation these enlarged endosomes (as well as inhibited co-localization with EGFR on 
the internalized since there was no internalization via the clathrin coated vesicle), while 
having very miniscule effect when high EGF was employed or when the contribution of 
CME is very minimal (compare Figure 32: D1-D3 to Figure 32: E1-E3). 
Second, inhibition of caveolin (by using filipin) when the predominant route of 
endocytosis is through CME (when stimulation of EGF is low), should not perturb 
activation of Rab5 significantly and it does not (Figure 30b). However, since CavME has 
some contribution to the clathrin independent endocytosis of EGFR when the 
concentration of EGF is high, it should be of no surprise that inhibiting caveolin during 
this time also has an impact on activation of Rab5 (Figure 30b). Similarly, when 
comparing formation of enlarged Rab5-positive endosomes in intact cells, we saw that 
filipin had very little impact when low EGF (when mainly CME is taking place) was used 
in comparison when High EGF was used and when some CavME is taking place 
(compare Figure 32: H1-H3 to Figure 32: I1-I3). 
Lastly, however, Rab5 can be activated when both CME and CavME pathways are 
inhibited. Since dynamin is an integral part of both CavME and CME, utilization of 
dynasore (a specific inhibitor of dynamin) and high EGF has introduced at least a third 
potential pathway through which Rab5 can be activated through (Figure 30c). However, 
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because there are no commercially available specific inhibitors of CLIC pathways, 
discerning which other pathway(s) can contribute to activation of Rab5 when there is 
high concentration of EGF available at the cell surface. A similar result was observed 
when the effect that dynasore had on formation of enlarged Rab5-positive endosomes in 
intact cells was compared during low and high EGF availability (Figure 32: F1-F3 to 
Figure 32: G1-G3). 
To further understand activation of Rab5 during Low or High ligand availability, the 
effect of overexpression or depletion of some GEFs (namely Rabex-5 and Rin1) was 
assayed on activation of Rab5. Overexpression of either GEF even without presence of 
any ligand at all or in presence of any of the aforementioned inhibitors, caused activation 
of Rab5 (Figure 33). However, any stimulation with either Low or High EGF increases 
the amount of active Rab5, though there does not to be a significant difference between 
the two ways of stimulation or between any of the previously mentioned pathways of 
endocytosis. On the other hand, depletion of either GEF by using siRNA prevents 
activation of Rab5 via either pathway of stimulation meaning that both Rabex-5 and Rin1 
both play essential roles in activation of Rab5, regardless of which pathway of 
endocytosis is employed (Figure 34). 
Since our lab has discovered the presence two splice variants of Rabex-5 (which we 
have termed Rabex-5: Short and Rabex-5: Long) in addition to the one which has 
previously been described in literature (which we have termed Rabex-5: FL), the effect 
these splice variants had on activation of Rab5 was assessed with respect to availability 
of ligand at the plasma membrane. As shown in Figure 35a, the splice variant which has 
been extensively used to characterize structure and function of Rabex-5 is termed here 
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Rabex-5: Full Length (or Rabex-5: FL), in addition to the Rabex-5: Short splice variant 
(because it is missing 39 amino acids in comparison to Rabex-5: FL) and Rabex-5: Long 
splice variant (which contains extra 177 extra amino acids in comparison to Rabex-5: 
FL). Of the missing amino acids which are absent in Rabex-5: Short, 31 are in the region 
between the MIU (Motif Interacting with Ubiquitin) and MBM (Mebrane Bound Motif) 
motifs and 8 are in the terminal region of Vacuolar sorting protein 9 (Vps9) domain, 
hence it is not surprising that in in comparison to Rabex-5: FL and Rabex-5: Long, 
Rabex-5: Short splice variant is not as efficient in activating Rab5 in absence of EGF 
(Figure 35b). When I compared the co-localization of Rab5 with Rabex-5 (either FL, 
Long or Short) in intact cells I saw that when there is no EGF or low concentration of 
EGF available, the Short splice variant (and to some the extent Long splice variant at 
Low EGF) poorly co-localize with Rab5 in comparison to Rabex-5: FL. On the other 
hand, when high concentration of EGF was available to the cells, the Long (and to a 
lesser extent the Short splice variant) co-localize much better with Rab5 (Figure 36). This 
could mean that the three spice variants are evolutionarily conserved to be redundant as it 
has been shown to be the case with other small GTPases. Furthermore, if endosome size 
of cells is compared to those that were overexpressing one of the three splice variants of 
Rabex-5 when not stimulated with EGF or when stimulated with low/high concentrations 
of EGF to cells expressing endogenous levels of Rabex-5: FL, a significant decrease in 
size of the Rabex-5: Short splice variant expressing cells was observed (Figure 37). 
Subcellular fractionation of cell lines overexpressing each splice variant shows a similar 
pattern as both Rabex-5: FL and Rabex-5: Long spice variants show accumulation of 
Rabex-5 in the membrane fraction for Low and High EGF (Figure 38). On the other 
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hand, for Rabex-5: Short splice variant, there did not appear to be much of a change at 
high EGF between cytosol and membrane fractions (Figure 38), giving further proof to 
our initial observation that Rabex-5: Short splice variant may not be necessary or able to 
activate Rab5 during endocytosis of EGFR at high concentrations of EGF. 
In conclusion, I have taken advantage of the well-characterized trafficking 
pathways of the EGF receptor, in order to assay the differential activation of Rab5. I have 
shown that activation of Rab5 is dependent on temperature, time of uptake as well as the 
concentration of ligand available at the cell surface. Furthermore, by utilizing specific 
inhibitors against key regulators of endocytosis (Dynasore hydrate, Chlorpromazine 
hydrochloride and Filipin) and by varying the concentration of EGF stimulation, I have 
provided evidence for the existence of at least three distinct pathways of Rab5-dependent 
internalization of growth factor receptors, however, due to the lack of availability of 
specific inhibitors of other less common endocytic pathways, further discrimination of 
Rab5 activation can not be determined. On the other hand, overexpression of either Rin1 
or Rabex-5 is able to rescue Rab5 activity even in absence of EGF and/or in the presence 
of any of the employed inhibitors, but that Rabex-5: Short splice variant was not as good 
in activating Rab5. Taken together, these results constitute evidence for the first time 
showing selective activation of Rab5 with respect to the different routes of uptake of 
EGFR as well as differential activation of Rab5 by three Rabex-5 splice variants. 
  
120 
 
 
Figure 26. Endocytosis of EGF-Receptor. EGF-Receptor can be internalized through 
different pathways, depending on the concentration of ligand available to the cell. If the 
concentration of EGF is Low (2ng/ml), the primary endocytic route will be through 
Clathrin Mediated Endocytosis (CME). However, if the concentration of EGF is high 
(>100ng/ml), the receptor will be internalized primarily via various clathrin independent 
(CI) pathways, however some could still get in via CME. Internalized vesicle containing 
EGFR will then fuse with the early endosome prior to either being recycled to the cell 
surface or degraded in the lysosome.  
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Figure 27. Effect of EGF on activation of Rab5. NR6-EGFR cells were transfected 
with Rab5, incubated with varying amounts of EGF (0, 2, 10, 50 and 100 ng/ml) at 4oC 
for 60 min, washed with PBS and incubated for 5 minutes at 37oC. They were 
subsequently washed with PBS, lysed and bound to glutathione beads in the presence of 
GST alone or GST-EEA1 at 4oC for 60 minutes. After incubation, beads were again 
washed with PBS and the presence of activated Rab5 was analyzed by western blot. 
Relative levels of these proteins were determined by densitometry. Data represents the 
mean ± SD of three independent experiments. 
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Figure 28. Temporal activation of Rab5 based on varying amounts of EGF. NR6-
EGFR cells were transfected with GFP-Rab5a, incubated with either 2ng/ml or 100ng/ml 
of EGF at 4oC for 60 minutes, washed with PBS and incubated for 0, 1, 2.5, 5 or 10 min 
at 37oC. They were subsequently washed with PBS, lysed and bound to glutathione beads 
in the presence of GST alone or GST-EEA1 at 4oC for 60 min. After incubation, beads 
were again washed with PBS and the presence of activated Rab5 was analyzed by 
western blot. The total cell lysate was also used to assay relative amounts of 
phosphorylated EGFR in each condition. Relative levels of these proteins were 
determined by densitometry. High EGF is based on the primary Y-axis and Low EGF 
corresponds to the secondary Y-axis. Data represents the mean ± SD of three independent 
experiments. 
  
123 
 
 
Figure 29. Effect of Temperature on Activation of Rab5. NR6-E cells were transfected 
with Rab5, incubated with 100ng/ml of EGF at 4oC for 60 min, washed with PBS and 
incubated for 5 minutes at 37oC. They were subsequently washed with PBS, lysed and 
bound to glutathione beads in the presence of GST alone or GST-EEA1 at 4oC for 60 
minutes. After incubation, beads were again washed with PBS and the presence of 
activated Rab5 was analyzed by western blot. Relative levels of these proteins were 
determined by densitometry. Data represents the mean ± SD of three independent 
experiments.  
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Figure 30. Effect of inhibitors of endocytosis on activation of Rab5.  NR6-E cells 
were transfected with GFP-Rab5a, pretreated with either: a) Chlorpromazine [20μM], b) 
Filipin [5μg/ml], c) Dynasore [80μM] or d) combination of the three inhibitors for 30 
minutes at 4oC, incubated with 2ng/ml or 100ng/ml of EGF at 4oC for 60 min, washed 
with PBS and incubated for 2.5 min at 37oC. They were subsequently washed with PBS, 
lysed and bound to glutathione beads in the presence of GST alone or GST-EEA1 at 4oC 
for 60 min. After incubation, beads were again washed with PBS and the presence of 
activated Rab5 was analyzed by western blot. Relative levels of these proteins were 
determined by densitometry. Data represents the mean ± SD of three independent 
experiments  
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Figure 31. Effect of siRNA knockdown of Caveolin and Dynamin on activation of 
Rab5. NR6-E cells were transfected with GFP-Rab5a, and then with siRNA against 
Caveolin 1, Dynamin 2 (or a combination) and incubated with 2ng/ml or 100ng/ml of 
EGF at 4oC for 60 min, washed with PBS and incubated for 2.5 min at 37oC. They were 
subsequently washed with PBS, lysed and bound to glutathione beads in the presence of 
GST alone or GST-EEA1 at 4oC for 60 min. After incubation, beads were again washed 
with PBS and the presence of activated Rab5 was analyzed by western blot. Relative 
levels of these proteins were determined by densitometry. Data represents the mean ± SD 
of three independent experiments. 
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Figure 32: Effect of inhibitors of endocytosis on the formation of enlarged Rab5-
posotive endosomes. NR6-E cells were transfected with GFP-Rab5a, pretreated with 
either: no inhibitor (A-C), Chlorpromazine [20μM] (D, E), Dynasore (F, G) [80μM], 
Filipin (H, I) [5μg/ml], Chlorpromazine & Dynasore (J,K) or Chlorpromazine and Filipin 
(L, M) for 30 min at 4oC, incubated with 0 (A), 2ng/ml (B, D, F, H, J, L) or 100ng/ml (C, 
E, G, I, K, M) of EGF at 4oC for 60 min, washed with PBS and incubated for 2.5 min at 
37oC. They were subsequently washed with PBS, fixed with 4% paraformaldehyde for 20 
min at room temperature, permeabilized with 0.1% Triton X-100 prior to incubation with 
the antibodies. Primary antibody used was rabbit anti EGF Receptor, while secondary 
antibody used was Alexa594 labeled goat anti-rabbit IgG antibody. GFP-Rab5a (1); 
immunofluorescence against EGFR (2); merge (3). 
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Figure 32 Continued 
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Figure 33. Effect of overexpression of Rabex-5 or Rin1 on activation of Rab5. a) 
NR6-E cells expressing either Rabex-5: FL or Rin1: FL were transfected with Rab5a, 
incubated with 2ng/ml or 100ng/ml of EGF at 4oC for 60 min, washed with PBS and 
incubated for 2.5 min at 37oC. They were subsequently washed with PBS, lysed and 
bound to glutathione beads in the presence of GST alone or GST-EEA1 at 4oC for 60 
min. After incubation, beads were again washed with PBS and the presence of activated 
Rab5 was analyzed by western blot.  b) NR6-E cells expressing either Rabex-5: FL or 
Rin1: FL were transfected with Rab5a, pretreated with either: Chlorpromazine [20μM], 
Dynasore [80μM] or Filipin [1mg/ml] for 30 min at 4oC, incubated with 2ng/ml or 
100ng/ml of EGF at 4oC for 60 min, washed with PBS and incubated for 2.5 min at 37oC. 
They were subsequently washed with PBS, lysed and bound to glutathione beads in the 
presence of GST alone or GST-EEA1 at 4oC for 60 min. After incubation, beads were 
again washed with PBS and the presence of activated Rab5 was analyzed by western blot. 
Relative levels of these proteins were determined by densitometry. Data represents the 
mean ± SD of three independent experiments. 
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Figure 34. Effect of silencing of Rabex-5 or Rin1 on activation of Rab5. NR6-E cells 
were transfected with either A) Rabex-5 or B) Rin1 siRNA, incubated with 2ng/ml or 
100ng/ml of EGF at 4oC for 60 min, washed with PBS and incubated for 2.5 min at 37oC. 
They were subsequently washed with PBS, lysed and bound to glutathione beads in the 
presence of GST alone or GST-EEA1 at 4oC for 60 min. After incubation, beads were 
again washed with PBS and the presence of activated Rab5 was analyzed by western blot 
C) Since endogenous levels of Rin1 were not detectable, immunoprecipitation of total 
cell lysate using ProteinG beads and monoclonal Rin1 antibody was also performed to 
check for siRNA efficacy.  
  
A C B 
Rab5: GTP 
Rabex-5 
Rab5: Total 
Low EGF 
High EGF 
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Figure 35. Effect of Rabex-5 splice variants on activation of Rab5. a) Primary 
structure of Rabex-5 splice variants. The Short and the Long splice variants contain extra 
40 amino acids between the MIU and MBM domains in comparison to Rabex-5: FL, 
whereas Rabex-5 short is missing the terminal 124 amino acids in comparison to Rabex-
5: FL and Rabex-5: Long. b) Rabex-5 splice variants differentially activate Rab5. NR6-E 
cells expressing Rabex-5 in absence of EGF stimulation were lysed and bound to 
glutathione beads in the presence of GST alone or GST-EEA1 at 4oC for 60 min. After 
incubation, beads were again washed with PBS and the presence of activated Rab5 was 
analyzed by western blot. Relative levels of these proteins were determined by 
densitometry. Data represents the mean ± SD of three independent experiments. 
A 
B 
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Figure 36. Effect of Rabex-5 splice variants on formation of Rab5 positive 
endosomes. I) Confocal Images showing co-localization of Rabex-5 and Rab5. NR6E 
cell lines expressing either Rabex-5: FL, Rabex-5: Long or Rabex-5: Short splice variant 
were transfected with GFP-Rab5wt, after which EGF uptake was carried out using 0, 2 or 
100ng/ml of EGF for 2.5min at 37oC. Cells were fixed with paraformaldehyde and 
immunofluorescence was performed using anti Rabex-5 rabbit polyclonal primary and 
goat anti rabbit Alexa594 secondary antibody. A-Rabex-5: Full Length; B-Rabex5: Long 
splice variant; C-Rabex5: Short splice variant; 1- No EGF; 2-Low EGF; 3-High EGF. II) 
Pearson correlation coefficients showing co-localization of Rab5 with Rabex-5 from each 
condition. 
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Figure 37. Effect of Rabex-5 splice variants on perimeter of Rab5-positive 
endosomes. Perimeters of Rab5-positive endosomes from at least 200 cells were 
measured using the NIH Image J software from immunofluorescence images acquired 
using a Leica TCS SP2 confocal microscope in NR6 cells for each experimental 
condition. Histograms of Rab5-positive endosomes vs. the endosome size were 
determined in NR6-E cells expressing Rab5 wild type (WT) containing either Rabex-5: 
FL, Rabex-5: Long or Rabex-5: Short splice variants in the absence or in the presence of 
either 2 or 100 ng/ml EGF.   
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Figure 38. Subcellular Distribution of Rabex-5 splice variants. NR6-E cells 
expressing either Rabex-5: FL (FL), Rabex-5: Long (L) or Rabex-5: Short (S) splice 
variants were incubated with 0, 2 or 100 ng/ml EGF as described in Materials and 
Methods. After treatment, cells were washed with ice cold PBS and incubated at 37oC for 
5 minutes. Cells were then washed again using ice-cold PBS, homogenized and 
membrane fractions were prepared as described in Materials and Methods. Membrane 
[M] and cytosol [C] fractions were treated with sample buffer and proteins were subject 
to SDS-PAGE, blotted to a nitrocellulose membrane, and antibodies specific to Rabex-5, 
phospho(p)-EGF-receptor, total(t)-EGF-receptor, and tubulin were used to visualize these 
proteins by Western blot analysis. Relative levels of these proteins were determined by 
densitometry. Data represents the mean ± SD of four independent experiments.  
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CHAPTER 4 
THE EFFECT OF RABEX-5 ON SEVERAL BIOLOGICAL PROCESSES  
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4.1 Abstract 
Alarming increases in global incidence of obesity-related health issues have also 
sparked immense interest into understanding the mechanisms behind the differentiation 
of pre-adipocytes into mature adipocytes, a process known as adipogenesis. Along the 
same lines, as humans are living longer and as the median age of the global world 
population is increasing, it should be of no surprise that the frequency of common 
neurodegenerative disorders (such as Parkinson’s and Alzheimer’s disease) has also been 
steadily rising. The Rab superfamily of small GTPases is a key regulator of numerous 
cellular trafficking processes including the endocytosis of GLUT4 and TrkA vesicles. 
Since Rab proteins play a critical role in vesicle trafficking, it may be fair to assume that 
they also may represent a site of integration for signals from insulin and TrkA receptor as 
well as signaling endosome biogenesis. Although extensive research has been centered on 
both adipogenesis as well as neurogenesis (and subsequently GLUT4 and TrkA 
trafficking), the specific role of Rab5, the master regulator of endosome biogenesis, in 
both of the aforementioned processes has yet to be determined. Here we investigated the 
role of Rabex-5, a Rab5 guanine nucleotide exchange factor that facilitates the exchange 
of GDP for GTP and thereby activates Rab5, in adipogenesis and neurogenesis. We 
found that Rabex-5 inhibits differentiation of both 3T3-L1 and PC12 cells not only by 
activating Rab5 and promoting degradation of the signaling endosome, but also by 
ubiquitinating Ras and inhibiting the Ras signaling cascade that is crucial for cellular 
differentiation. Further research may be needed to elucidate the full mechanism of 
Rabex-5 action in adipogenesis and neurogenesis as it may become a pharmaceutical 
target in battling obesity and various neurodegenerative disorders.   
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4.2 Introduction 
Since there has been a global rise in obesity-associated health issues [Kelly et al., 
2008; Popkin et al., 2010; Flegal et al., 2010; Shao & Chin 2011], the topic of 
adipogenesis has been getting an increasing amount of interest, which in turn has resulted 
in numerous advances in stem cell technology, cell isolation and identification, as well as 
trans-differentiation. One of the best studied and most established cell lines are the 3T3-
L1 pre-adipocytes, which are a continuous sub-strain of 3T3 (Swiss albino) that were 
developed through clonal isolation. 3T3-L1 pre-adipocytes have no significant lipid 
content and resemble fibroblasts, but when cultured to differentiate, they undergo a pre-
adipose to adipose like conversion while progressing from a rapidly dividing to a 
confluent and contact inhibited state that makes them are suitable for metabolic studies 
[Green & Meuth, 1974].  
Upon maturation, white adipocytes contain a single, massive lipid droplet that looks 
as if it comprises most of cell volume which thereby adding to the buoyance of the 
adipocyte. This makes it very difficult to culture and perform metabolic assays on, 
because the lipid-containing adipocytes tend to float and detach from their respective 
culture plates [Fernyhough et al., 2005]. Hence, most metabolic assays are not performed 
on fully mature adipocytes, but on those which are less buoyant and still able to adhere to 
culture plates. In general, most adipocytes possess a great capability to store immense 
volumes of lipid, which can subsequently be utilized by high priority tissues.  
Variations in circulation of several hormone levels (such as insulin, thyroxine or 
growth hormone) as well as some glucocorticoids (such as dexamethasone) have been 
shown to often result in astonishing differences in the development of adipose tissue, 
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because they all can stimulate adipocyte differentiation by triggering DNA replication, 
reentry of the cell cycle (a process known as mitotic clonal expansion), and a 
transcription factor cascade that ultimately leads to expression of various adipocyte genes 
[Mattsson & Olsson, 2007; Hausman et al., 2009; Poulos et al., 2010; Tang & Lane, 
2012]. Lastly, elevation of cAMP (via activation of cAMP signaling pathways by 
supplementing the differentiation media with fetal calf serum) has also been shown to 
have a significant impact on induction of differentiation in 3T3-L1 pre-adipocytes 
[Student et al., 1980; MacDougald & Lane, 1995; Tang & Lane, 2012].  
In a regular cycle of adipocyte differentiation, shortly (less than 5 minutes) after the 
induction of differentiation by a media cocktail containing (insulin or IGF-1, 3-isobutyl-
1-methylxanthine (more commonly referred to as IBMX) and dexamethasone), 
phosphorylation of CREB (cAMP response element binding protein) causes activation 
and expression of transcription factor C/EBPβ (CCAAT/enhancer-binding protein beta) 
causing growth arrest [Zhang et al., 2004]. Next, MAPK (Mitogen Activated Protein 
Kinase) and then GSK3β (Glycogen synthase kinase 3 beta) phosphorylate C/EBPβ on 
Thr 188 or Thr 179 and Ser 187 [Tang et al., 2005] respectively, which thereby acquires 
DNA-binding activity and the pre-adipocytes synchronously re-enter the cell cycle. 
MAPK phosphorylation has been shown to occur within 4 hours of induction and is 
required for mitotic clonal expansion, C/EBPβ DNA binding activity and terminal 
differentiation while dual phosphorylation of GSK3β, which occurs between 12-16 hours 
of induction, is what actually leads to acquisition of DNA-binding activity. At about 16–
20 hours after induction, pre-adipocytes synchronously reenter the cell cycle and undergo 
several rounds of mitosis, referred to as mitotic clonal expansion. As a failsafe 
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mechanism to prevent the acquisition of DNA-binding activity of C/EBPβ until the pre-
adipocytes have entered the mitotic clonal expansion, CHOP10 (C/EBP homologous 
protein 10) forms a heterodimer with C/EBPβ until pre-adipocytes reach the mitotic 
clonal expansion stage [Tang & Lane, 2000]. As C/EBPβ and C/EBPδ increase in 
expression, C/EBPβ stimulates expression of PPARγ (peroxisome proliferator-activated 
receptor γ), which in complex with RXRα (retinoid x receptor alpha, a member of the 
nuclear receptor subfamily 2B1) induces expression of C/EBPα but reduces the 
expression of both C/EBPβ and C/EBPδ [Brun et al., 1996; Tang & Lane 2012]. In the 
end, C/EBPα and PPARγ reciprocally regulate one another to ensure that adipocytes are 
maintained in a differentiated state [Pouols et al., 2010; Tang & Lane, 2012]. The cells 
then exit the cell cycle, lose their fibroblast-like appearance, commence accruing 
cytoplasmic triglyceride, and attain the look and metabolic structures of adipocytes by 
activating SREBP (sterol regulatory element binding protein 1c, a helix-loop-helix 
leucine zipper protein which regulates lipogenesis) [Green & Kehinde, 1974; Student et 
al., 1980; Tang & Lane 2012]. Triglyceride accumulation has also been shown to be very 
closely associated with an organized escalation in expression of the enzymes required for 
fatty acid and triacylglycerol biosynthesis [Student et al., 1980; MacDougald & Lane 
1995]. Similarly, several regulatory proteins, are also expressed, including insulin 
receptors [Reed & Lane, 1980], the insulin responsive glucose transporter GLUT4 
[Kaestern et al., 1989; Millar et al., 1999], leptin [Hwang et al., 1997], among others. The 
adipocyte differentiation cascade is also summarized in Figure 39. 
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By increasing the localization of the GLUT4 (a glucose transporter) to the plasma 
membrane, insulin has been shown to stimulate transport of glucose in adipocytes as well 
as striated muscle [Bryant et al., 2002]. In the absence of insulin, GLUT4 undergoes 
endocytosis, where part of the intracellular GLUT4 resides in the common endocytic 
compartments, whereas the other half is found in a specialized GLUT4 storage 
compartment which lacks the common endocytic markers [Martin et al., 1996; Zeigerer et 
al., 2002; Lodhi et al., 2007]. Recently, it has been shown that the two pools of GLUT4 
are in equilibrium which is accomplished through uninterrupted cycling and fusion that 
stimulates intracellular retention of GLUT4 [Karylowski et al., 2004]. Insulin permits 
escape from the aforementioned cycle, thereby promoting trafficking of GLUT4 positive 
vesicles to the cell surface [Lodhi et al., 2007]. The stimulation of glucose transport by 
insulin causes the tyrosine phosphorylation of adaptor proteins (from the insulin receptor 
substrate family), resulting in localization and activation of both PI3K 
(phosphatidylinositol 3-kinase) as well as PI3P- (phosphatidylinositol 3-phosphate) 
dependent processes [Kelly et al., 1992; Kelly & Ruderman, 1993; Lodhi et al., 2007]. 
On the other hand, as humans are living longer and as the median age of the global 
world population is increasing, it should be of no surprise that the frequency of common 
neurodegenerative disorders (such as Parkinson’s and Alzheimer’s disease) has also been 
steadily rising [Sloane et al., 2002; Brookmeyer et al., 2007; Allen et al., 2011], since the 
greatest risk factor for the aforementioned dementias is age. Hence, there is paramount 
interest in elucidating the mechanisms behind these debilitating dementias, as a dramatic 
rise in median age of the world’s population will lead to a dramatic increase in the 
prevalence of these dementias in the upcoming years with the potentially unbearable 
148 
 
resulting impacts on global healthcare, since there is no known cure for the 
aforementioned ailments. 
Neurotrophins, apart from being indispensable for development of the nervous 
system, are also key for survival, maintenance and regeneration of adult neurons. 
Furthermore, fluctuations in expression of neurotrophins have been associated with the 
pathogenesis of several neurodegenerative disorders (such as Alzheimer’s disease), but 
on the other hand, have also offered a therapeutic answer for others (such as multiple 
sclerosis) [Kalinowska-Lyszczarz, 2012]. Of particular interest is the nerve growth factor 
(NGF), which has been shown to mediate learning, memory and other higher brain tasks, 
as well as to influence survival and differentiation of neurons in rat pheochromocytoma 
PC12 as well as human neuroepithelioma SK-N-C cells [Huang & Reichardt, 2001; 
Segal, 2003; Berry et al., 2012].  It has previously been shown that NGF binds to its 
receptor TrkA with high affinity and is internalized via receptor mediated endocytosis 
into signaling endosomes in order to sustain cell signaling and neurite outgrowth [Layer 
& Shooter, 1982; Zhang et al., 2000]. Furthermore, it is known that the aforementioned 
signaling endosomes escape the canonical fusion with late endosomes and subsequent 
degradation in lysosomes [Liu et al., 2007], possibly by inhibiting activity of Rab5 (a 
small GTPase that is essential for early endosome fusion and subsequent entry to the 
degradative endocytic pathway), however biogenesis of signaling endosomes is currently 
poorly understood. 
The Rab superfamily of small GTPases is a key regulator of numerous cellular 
trafficking processes including the endocytosis of GLUT4 and TrkA vesicles [Dugani 
and Klip, 2005]. Rabs switch between an active (GTP-bound) and an inactive (GDP-
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bound) form, which is regulated by guanine nucleotide exchange factors (GEFs) that 
promote exchange of GDP for GTP, and GTPase-activating proteins (GAPs) that speed 
up the intrinsic GTPase activity of Rabs. Since Rab proteins play a critical role in vesicle 
trafficking, it may be fair to assume that they also may represent a site of integration for 
signals from insulin and TrkA receptor as well as signaling endosome biogenesis. In 
particular, Rab5 is known to promote early endosome fusion and is essential in promoting 
entry into the late endosome and lysosome degradative pathway [Bucci et al., 1995; 
Barbieri et al., 1996]. Although extensive research has been centered on both 
adipogenesis as well as neurogenesis (and subsequently GLUT4 and TrkA trafficking), 
the specific role of Rab5, the master regulator of endosome biogenesis, in both of the 
aforementioned processes has yet to be determined. Rabex-5, a well-established GEF for 
Rab5, catalyzes the exchange of GDP for GTP and in doing so activates Rab5, but also 
stabilizes it on early endosomes and in doing so recruits other effector proteins to the 
early endosome in order for specialized trafficking functions to be carried out [Jovic et 
al., 2010]. Lambright’s group has shown that activation of Rab5 is done through the Vps9 
catalytic domain and that the highly conserved amino acids D313, P317, Y354 and Y357 
are vital in maintaining the full GEF activity of Rabex-5 [Delprato et al., 2004]. 
Furthermore, Rabex-5 has been shown to inhibit Ras signaling [Colicelli, 2010] via the 
ubiquitin ligase activity of its ZnF domain and in doing so shown to be important in 
establishing organism size, wing vein pattern and eye versus antennal fate in Drosophila 
[Yan et al., 2010]. Therefore, we were interested in investigating the role of Rabex-5 in 
differentiation of 3T3-L1 pre-adipocytes into adipocytes as well as in neurite outgrowth 
of PC12 cells. 
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4.3 Materials and Methods 
4.3.1 Cell Culture and Materials  
3T3L1 murine pre-adipocytes cells were grown in DMEM supplemented with 10% 
fetal calf serum supplemented with 2mM L-Glutamine and 1% pen/strep. PC12 cells 
were grown in DMEM supplemented with 10% horse serum and 5% fetal calf serum and 
1% pen/strep. Rab5, Rabex-5, α-Tubulin, C/EBPα, PPARγ and phospho-EGFR 
antibodies were from Cell Signaling Technology (Beverly, MA). Rin1 antibody was 
purchased from Abcam Inc. and total EGFR antibody was from Santa Cruz 
Biotechnology Inc (Santa Cruz, CA). NGF was purchased from Merk KGaA (Darmstadt, 
Germany). All HRP labeled secondary antibodies were purchased from Jackson 
ImmunoResearch Laboratories (West Grove, PA). All other chemicals were purchased 
from Sigma (St. Louis, MO) unless otherwise noted.  
4.3.2 3T3-L1 differentiation protocol 
3T3-L1 pre-adipocytes were seeded in either 6 or 12 well plates at about 2-4 x 104 
cells/cm2 and induced to differentiate 48 hours post confluent using growth media 
supplemented with insulin, dexamethasone and IBMX for 48 hours. Cells were then fed 
growth media supplemented with insulin, with fresh media being added every other day 
until day 10, when they were either subject to lysing (20 mM Tris-HCl (pH 7.5), 150 mM 
NaCl and 1% Triton x-100), SDS-PAGE and subsequent western blotting or stained with 
Oil Red-O for lipid quantification as previously described [van Goor et al., 1986].  
 
 
151 
 
4.3.3 PC12 differentiation 
PC12 pheochromocytoma cells were seeded in either 6 or 12 well collagen coated 
plates at about 2-4 x 104 cells/cm2 and grown until 70-80% confluent with growth media 
being changed every 48 hours. To induce differentiation growth media was replaced with 
differentiation media (DMEM supplemented with 1% Horse serum, 0.5% calf serum, 1% 
pen/strep and 50ng/ml NGF) and changed every 48 hours for 6 days as previously 
described [Green & Tischler, 1982; Obin et al., 1999]. Cells were then either fixed in 
paraformaldehyde for image analysis or subject to SDS-PAGE and subsequent western 
blotting. 
4.3.4 Western Blot analysis 
To prepare whole cell lysates, cell were washed twice with ice-cold PBS and lysed in 
ice-cold lysis buffer (20mM Tris- HCl pH 7.5, 150mM NaCl, 1% Triton X-100). The 
lysates were clarified by centrifugation, and protein concentrations were determined 
using the BCA Protein Assay Reagent Kit (Pierce). Proteins were resolved by SDS-
PAGE and transferred to nitrocellulose membranes, which were blocked and probed with 
the indicated antibodies. To determine relative protein amounts, three representative 
exposures for each sample were quantified using National Institutes of Health ImageJ 
software. 
4.3.5 Cell proliferation 
3T3-L1 cells expressing Rabex-5: FL, Rabex-5: Long or Rabex-5: Short splice 
variants were seeded at 5 x 105 cells in a 12 well dish. Cells were then grown for 48 
hours, after which they were treated with MTT reagent for 2 hours and lysed using cell 
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lysis buffer containing 10% SDS and 0.01M HCl. Relative proliferation was then 
quantified by spectrophotometry.   
4.3.6 Cell Imaging and analysis 
Images of fixed cells were obtained using the DeltaVision Elite wide field microscope 
under differential interference contrast illumination. The number of differentiated PC12 
cells was determined visually by counting cells that had at least one neuronal process 
with a length that was twice the cell body diameter, and expressed it as a percentage of 
the total cells within that field of view. Neuronal process growth was determined by 
physically tracing the length of the longest process per cell (using NIH ImageJ software) 
for all cells in a field of view which had at least one distinguishable neuronal process and 
for which the entire neuron could be visualized [as previously described by Das et al., 
2004].  
4.4 Results 
4.4.1 Rabex-5 splice variants selectively inhibit adipogenesis through activation of Rab5 
and ubiquitination of Ras. 
Because Over-expression of Rab5 can inhibit differentiation of fat cells, I wanted to 
assay the effect that an activator of Rab5, Rabex-5, might have on adipogenesis in 3T3-
L1 cells (add your ref here). First, I compared the expression level of Rabex-5 in control 
undifferentiated 3T3-L1 fibroblasts to differentiated Day 9 3T3-L1 and noticed that the 
relative expression of Rabex-5 decreases significantly (Figure 40). I then repeated the 
experiment but lysed the cells at Days 1, 3, 5, 7 and 9 and observed that as cells undergo 
differentiation, the expression level of Rabex-5 decreases (Figure 40).   
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Because Rabex-5 expression decreases as adipogenesis increases, it was hypothesized 
that expression of Rabex-5 in 3T3-L1 cells should inhibit the differentiation of 3T3-L1 
pre-adipocytes into mature adipocytes. Furthermore, two new splice variants of Rabex-5 
(here termed Rabex-5: Short and Rabex-5: Long) in addition to the already published and 
well characterized splice variant (here termed Rabex-5:FL), I wanted to not only assay 
whether Rabex-5 inhibits adipogenesis, but also whether these splice variants selectively 
inhibit adipogenesis. When I quantified adipogenesis by staining the cells with Oil Red-
O, I observed that although all three splice variants are able to inhibit adipogenesis; 
Rabex-5: FL and Rabex-5: Long splice variant inhibit adipogenesis about 20-30% better 
than Rabex-5 Short splice variant (Figure 41a). Adipogenic cells were lysed to measure 
adipogenic markers C/EBPα and PPARγ and compared to non-adipogenic cells. Rabex-5 
inhibited expression of transcription factors C/EBPα and PPARγ in comparison to control 
3T3-L1 adipocytes (Figure 41). 
In order to make sure that the observed inhibitory effect of Rabex-5 was not due to its 
potential ability to inhibit cellular growth and proliferation, MTT assay showed that the 
splice variants have no effect on the rate of cell proliferation (Figure 42). Because Rabex-
5: Short splice variant inhibited adipogenesis less than the other two splice variants and 
because Rabex-5: Short splice variant is missing two structural domains of the full length 
splice variant, deletion mutants of Rabex-5 were constructed in order to decipher which 
domain(s) were contributing to the inhibitory adipogenic effect of Rabex-5. I observed 
that both the N-terminus and the Vps9 domains significantly inhibited adipogenesis of 
3T3-L1 cells, but that the C-terminus had no effect (Figure 43). Because Rabex-5 
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interacts with Ras, 3T3-L1 cells expressing Rabex-5: FL exhibited an increase in 
ubiquitination compared to control fibroblast or Day 10 adipocytes after 
immunoprecipitation with ubiquitin (Figure 44). On the other hand, because the Vps9 
domain of Rabex-5 is the catalytic domain involved in activating Rab5, point mutations 
in the Vps9 domain in amino acid residues which have been shown to be important in the 
Rab5-Rabex-5 interaction were generated and could rescue the differentiation of 3T3-L1 
cells. The effective residue was Y354 (Figure 43).  
4.4.2 Rabex-5 splice variants selectively inhibit neurite outgrowth in rat PC12 cells 
Because of the inhibitor effect on Rabex-5 splice variants on differentiation of fat 
cells, the same effect may be true in other cell types, such as neuronal cells. In order to 
assay differentiation and neurite outgrowth of PC12 cells, between 4-5 x 105 cells were 
grown on glass coverslips that were previously coated with 4µg/ml Type IV Rat tail 
collagen, allowed the cells to adhere, and about 2 hours after attachment, changed the 
media from growth (DMEM supplemented with 10% horse serum, 5 % fetal calf serum 
and 1% pen/strep) to differentiation (DMEM supplemented with 1% horse serum, 0.5% 
calf serum, 1% pen/strep and 50ng/ml NGF). The media.was replenished every two days 
and on day 6 fixed the cells with 4% paraformaldehyde.  Images of neuronal processes 
were taken to measure neurite outgrowth and calculate the percentage of cells that had 
differentiated. Differeniated cells were those that had a neuronal process that was twice 
the diameter of the cell body (Figure 45). I observed that Rabex-5: FL and Rabex-5: Long 
splice variants both inhibited differentiation of PC12 cells (respectively by approximately 
25% and 30%), whereas Rabex-5: Short splice variant inhibited differentiation by only 
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about 10-15%. Furthermore, PC12 cells expressing the D313A mutation (from the Vps9 
domain of Rabex-5: FL) differentiated similarly to control PC12 cells (Figure 46) 
suggesting to the role of the Vps9 domain in PC12 differentiation.  
4.5 Discussion 
Because it has been previously shown that activation of Rab5 leads to an inhibition in 
adipogenesis, the effect Rabex-5, a Rab5 GEF, on differentiation of 3T3-L1 pre-
adipocytes was assayed. First 3T3-L1 cell lines expressing Rabex-5 were generated by 
retroviral infection. Next, cells were grown to confluency and induced to undergo 
differentiation by supplementing the growth media for the first three days with insulin, 
dexamethasone and IBMX and then for the next six days only with insulin. Cells were 
then either lysed and subject to subsequent western blotting (in order to check for 
adipogenic markers) or fixed and stained with Oil Red-O (in order to quantify the formed 
liposomes). As expected, in comparison to control 3T3-L1 adipocytes, the 3T3-L1 cells 
expressing Rabex-5 significantly inhibited adipogenesis (Figures 40 & 41).  In an 
experiment with differentiating neuronal pheochromocytoma cell line by using NGF, a 
similar result was obtained: Rabex-5 inhibited neurite outgrowth in PC12 cells (Figure 
46).  
Furthermore splice variants of Rabex-5 from human placenta (Rabex-5: Short and 
Rabex-5: Long) in addition to Rabex-5: FL were assayed with differentiating 3T3-L1 pre-
adipocytes; the two splice variants (Rabex-5: FL and Rabex-5: Long) which activate 
Rab5, also inhibit adipogenesis and neurogenesis, whereas Rabex-5: Short is also able to 
inhibit adipogenesis and neurogenesis, however significantly less (Figures 41 & 46). In 
order to rule out the possibility that the observed inhibitory effect of the selected Rabex-5 
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splice variants is merely due to the fact that they may affect the growth and proliferation 
of these cells, 3T3-L1 cell lines expressing Rabex-5: FL, Rabex-5: Long or Rabex-5: 
Short splice variants were seeded at 5 x 105 and subject to a cell proliferative MTT assay 
and it was observed that none of the splice variants affect the rate of cell proliferation 
(Figure 42).  
Because Rabex-5: Short splice variant is missing the terminal 130 amino acids (which 
comprise the last 5 amino acids of the Vps9 as well as the whole Coiled-Coil and Proline 
Rich domains), but is still able to inhibit adipogenesis by about 30%, a C-terminal 
deletion mutant was created in order to assess whether this domain contributes to the anti-
adipogenic effect of Rabex-5. C-terminus of Rabex-5 did not significantly affect 
adipogenesis (Figure 43). Additional deletion mutants of Rabex-5 were created in order 
to better understand both the anti-adipogenic and anti-neurogenic activity of Rabex-5. 
Hence, we created an N-terminal mutant (which contains the Ras ubiquitination 
domains), a Vps9 domain (which activates Rab5) from Rabex-5: FL mutant as well as the 
truncated Vps9 domain from Rabex-5: Short splice variant and observed that although the 
Vps9 domain (full or truncated) inhibits adipogenesis by about 40-50% and neurite 
outgrowth by about 30%, the N-terminal domain also possesses anti-adipogenic and anti-
neurogenic properties as well (Figures 43 & 46). Because ZnF and MIU domains of the 
N-terminus comprise the Rabex-5 ubiquitin ligase domain and essential in ubiquitination 
of Ras [Colicelli, 2010], it is plausible to assume that the Rabex-5 may inhibit 
differentiation of either fat or nerve cells via ubiquitination of Ras and thereby inhibition 
of Ras signaling. To support this evidence, the immunoprecipitation assay on 3T3-L1 
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fibroblast, 3T3-L1 adipocytes and 3T3-L1 adipocytes cells stably expressing Rabex-5 
increased ubiquitination of Ras with the Rabex-5 cell line (Figure 44). However, in order 
to confirm that it was the interaction of Rabex-5 with Rab5 which was causing the 
majority of adipogenic or neurogenic inhibition, point mutants were generated in the 
Vps9 domain, at amino acid residues which were previously shown to be key for intact 
activation of Rab5, those being D313, P317, Y354 and Y357 [Delprato et al., 2004]. The 
relative differentiation of 3T3-L1 pre-adipocytes as well as PC12 cells was also rescued 
in these mutants (Figure 43 & 46), suggesting that the interaction of Rabex-5 with Rab5 
is key in controlling the adipogenesis in 3T3-L1 and neurite outgrowth in PC12 cells. In 
conclusion, expression of Rabex-5 significantly inhibits adipogenesis and neurogenesis 
because: a) because the ZnF domain of Rabex-5 ubiquitinates Ras and thereby inhibits 
Ras signaling and b) more importantly because the GEF domain of Rabex-5 activates 
Rab5 and in doing so inhibits formation of signaling endosome and in turn promotes the 
fusion with degradative endosomal trafficking route.  
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Figure 39. Summary of the adipocyte differentiation cascade. Induction of pre-
adipocyte differentiation is initiated by supplementing the growth media with 
insulin/IGF, dexamethasone and IBMX, which causes and a phosphorylation of CREB 
(cAMP response element binding protein) and a decrease in CHOP10 (C/EBP 
homologous protein 10) allowing the pre-adipocytes to enter mitotic clonal expansion, 
which is followed by both an increase in C/EBPβ (CCAAT/enhancer-binding protein 
beta) as well as the dual phosphorylation of C/EBPβ first by MAPK and then by GSK3β 
(glycogen synthase kinase 3 beta). Phosphorylated C/EBPβ stimulates expression of 
PPARγ (peroxisome proliferator-activated receptor γ) which in turn stimulates expression 
of C/EBPα and subsequently reduces expression of C/EBPβ. PPARγ and C/EBPα then 
reciprocally regulate one another in order to ensure that adipocytes are maintained in a 
differentiated state, after which the cells exit the cell cycle, lose their fibroblast-like 
appearance, commence accruing cytoplasmic triglycerides, and attain the look and 
metabolic structures of adipocytes by activating SREBP (sterol regulatory element 
binding protein 1c, a helix-loop-helix leucine zipper protein which regulates lipogenesis) 
as well as several adipocyte genes (which include insulin receptors, GLUT4 and leptin, 
among others).   
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Figure 40. Expression of Rabex-5 in 3T3-L1 cells during adipogenesis. I) 3T3-L1 (A) 
cells or 3T3-L1 Rabex-5 cells (B) were stimulated to differentiate for 9 days after which 
they were fixed with paraformaldehyde, stained with Oil Red-O (ORO) and imaged using 
Leica phase contrast microscope, Retiga 1300R camera and QCapture imaging software. 
II) 3T3-L1 cells were stimulated to differentiate for 9 days and lysed at days 3, 5 and 9, 
subject to SDS-PAGE and subsequent western blotting with the relative expression level 
of Rabex-5 compared to undifferentiated 3T3-L1 fibroblasts.   
Tubulin 
Rabex-5 
Fibro Day 9 Day 3 Day 5 
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Figure 41. Rabex-5 inhibits differentiation of mouse 3T3L1 pre-adipocytes into 
adipocytes. Quantification of 3T3-L1 differentiation by Oil Red-O staining. 3T3-L1 cells 
or 3T3-L1 Rabex-5 cell lines were seeded at 5 x 105 in 12 well plates and grown to 
confluency and allowed to differentiate for 9 days. Differentiation was induced by 
supplementing the growth media with insulin, dexamethasone and IBMX at Days 1 and 
3, or only insulin at Days 5, 7 and 9, at which point they were fixed in paraformaldehyde, 
washed with PBS and stained with ORO.  ORO was eluted with isopropanol and relative 
differentiation was quantified by spectrophotometry. 
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Figure 42. Rabex-5 splice variants do not affect cell proliferation. 3T3-L1 cells 
expressing the respective Rabex-5 splice variant were seeded onto 12 well plates at 5 x 
105 cells and allowed to grow for 48hrs after which they were subject to MTT assay to 
quantify cell proliferation. The data represent an average of three independent 
experiments. 
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Figure 43. The Vps9 domain of Rabex-5 is essential in inhibiting differentiation of 
3T3-L1 pre-adipocytes into mature adipocytes. I) Quantification of 3T3-L1 
differentiation by ORO staining. 3T3-L1 cells or 3T3-L1 Rabex-5 cell lines were seeded 
at 5 x 105 in 12 well plates and grown to confluency and allowed to differentiate for 9 
days. Differentiation was induced by supplementing the growth media with insulin, 
dexamethasone and IBMX at Days 1 and 3, or only insulin at Days 5, 7 and 9, at which 
point they were fixed in paraformaldehyde, washed with PBS and stained with ORO.  
Cells were then washed with H2O, imaged using phase contrast DeltaVision Elite Wide-
Field microscope and SoftWorx imaging software, after which ORO was eluted with 
isopropanol and relative differentiation quantified by spectrophotometry (A: Control 
3T3-L1 adipocytes; B: Rabex-5: FL; C: Rabex-5: Short splice variant; D: Rabex-5: 
P317A; E: Rabex-5: FL Vps9; F: Rabex-5: Short Vps9).  II) 3T3-L1 cells or 3T3-L1 
Rabex-5 cell lines were seeded at 5 x 105 in 12 well plates and grown to confluency and 
allowed to differentiate for 9 days. Differentiation was induced by supplementing the 
growth media with insulin, dexamethasone and IBMX at Days 1 and 3, or only insulin at 
Days 5, 7 and 9. At Day 9 cells were lysed and subject to SDS-PAGE and subsequent 
western blotting in order to check the expression levels of adipogenic markers C/EBPα 
and PPARγ (Fibro- Control Fibroblasts; Adipo- Control adipocytes; FL- Full Length; S- 
Short; N- N terminus).  
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Figure 44. Rabex-5 increases ubiquitination of Ras in 3T3-L1 cells. 3T3-L1 cells or 
3T3-L1 Rabex-5 cell lines were seeded at 5 x 105 in 12 well plates and grown to 
confluency and allowed to differentiate for 9 days. Differentiation was induced by 
supplementing the growth media with insulin, dexamethasone and IBMX at Days 1 and 
3, or only insulin at Days 5, 7 and 9 after which they were subject to immunoprecipitation 
using polyclonal rabbit Rabex-5 antibody and IgG beads. Bound protein was eluted from 
the beads and subject to SDS-PAGE and subsequent western blotting using monoclonal 
ubiquitin antibody and monoclonal pan-Ras antibody.  
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Figure 45. Neurite outgrowth in rat pheochromocytoma PC12 cells. PC12 cells were 
seeded at 2 x 104 cells/cm2 onto collagen coated glass coverslips and allowed to 
differentiate for 6 days. Differentiation was induced by reducing the amount of serum in 
the media (from 10% to 1%) and supplementing it with 50ng/ml NGF, and replenished 
every 2 days for a total of 6 days. Cells were then fixed with paraformaldehyde either 
prior to differentiation, after two days of differentiation, after 4 days of differentiation 
and after 6 days of differentiation, washed with PBS and imaged using DeltaVision Elite 
wide field microscope under differential interference contrast illumination.  
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Figure 46. Rabex-5 inhibits neurite outgrowth in rat PC12 cells. PC12 cells and PC12 
Rabex-5 cell lines were seeded at 2 x 104 cells/cm2 on collagen coated glass coverslips 
and allowed to differentiate for 6 days. Differentiation was induced by reducing the 
amount of serum in the media (from 10% to 1%) and supplementing it with 50ng/ml 
NGF, and replenished every 2 days for a total of 6 days. Cells were then fixed with 
paraformaldehyde prior to differentiation, after two days of differentiation, after 4 days of 
differentiation and after 6 days of differentiation, washed with PBS and imaged using 
DeltaVision Elite wide field microscope under differential interference contrast 
illumination. A cell was termed differentiated, if the length of any one of its neuronal 
processes was twice the diameter of its cell body.  
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CHAPTER 5 
CONCLUSION 
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The ability of cells to respond to extracellular cues and internalize various materials 
via different pathways of endocytosis is essential for their normal function. Endocytosis 
of extracellular molecules has been shown to be involved in numerous cellular activities 
ranging from growth and division to differentiation and signal transduction. Therefore, 
understanding the mechanisms controlling endocytosis could prove vital in elucidating 
numerous debilitating diseases which arise from misregulation of the aforementioned 
cellular processes ranging from diabetes and Alzheimer’s to cancer. 
In this dissertation I examined how a small GTPase that is involved in control of early 
endocytic events is activated, and what effect it may have on differentiation of either fat 
cells or neuronal cells. Because activation of tyrosine kinases is a key feature in receptor 
signaling and membrane trafficking processes, and because it has been well established 
that Rab5 is the master regulator of endocytosis, it was important to understand if there 
was a correlation between the tyrosine kinase activity of receptor tyrosine kinases and 
activation or Rab5. By using specific inhibitors of tyrosine kinase activity of EGF- and 
insulin-receptors (AG1478 for EGF-receptor or AG1024 and HNMPA-(AM)3 for insulin-
receptor), they were able to block fusion of early endosomes and then correlate that to the 
inhibition of activation of Rab5. Furthermore, it was shown that by using a constitutively 
active form of Rab5 (Q79L), It was able to rescue endosome fusion upon addition of 
tyrosine kinase inhibitors both in a cell free system and in intact cells. Hence, the 
enzymatic activity of tyrosine kinase receptors (either EGF or insulin) is at least in part 
required for endosome fusion via activation of Rab5. 
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Depending on how much ligand is available to the receptor at the cell surface, the 
receptor-ligand complex can be internalized via number of distinct pathways. These 
pathways include the canonical clathrin mediated, caveolin mediated, clathrin and 
caveolin independent but dynamin dependent, clathrin/caveolin/dynamin independent, 
macropinocytic and phagotycic. Therefore, it was important to understand if Rab5 is 
responsible for endosome fusion from each of the aforementioned pathways. By using 
specific inhibitors and siRNA against the major coat proteins or scission proteins 
involved in each pathway, at least three distinct pathways through which Rab5 can be 
activated were identified. What’s more is that if one of the guanine nucleotide exchange 
factors for Rab5 (known as Rabex-5) is overexpressed, Rab5 can be activated no matter 
which pathway is blocked and the need for ligand stimulation of receptor tyrosine kinases 
is also abolished. The use of three splice variants of Rabex-5 was used to investigate the 
ability of each splice variant to activate Rab5. Because all three splice variants are able to 
activate Rab5 (although at different levels), it is plausible to assume that the three splice 
variants probably act as redundant activators of Rab5. Because Rab5 is such a key player 
in early endocytosis, it should be of no surprise that an evolutionarily conserved fail-safe 
mechanism of activation exists in order to make sure that this crucial protein is tightly 
regulated. 
Next, that if a constitutively active form of Rab5 is expressed in a pre-adipocyte 3T3-
L1 cell line, differentiation of pre-adipocytes into mature adipocytes is inhibited between 
50%-60% .  So then it was important to understand what role does the aforementioned 
activator of Rab5, Rabex-5, have in regulating adipogenesis. I have shown that a cell line 
stably expressing Rabex-5 also inhibits adipogenesis by about 50%.  Furthermore, the 
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inhibition of adipogenesis was correlated to activation of Rab5 by showing that 
expression of Rabex-5 mutants in the Vps9 domain which were previously shown to be 
essential in activation of Rab5, rescued adipocyte differentiation. The N-terminus of 
Rabex-5 alone, which does not have the guanine nucleotide exchange capabilities, was 
also able to inhibit adipogenesis. Since it is well established known that Rabex-5 can 
ubiquitinate Ras through the ZnF domain in its N-terminus, the data presented here 
showsthat in 3T3-L1 cells, Rabex-5 increases ubiquitination of Ras and in doing so 
interrupts the signaling cascade which would ultimately lead to expression of adipogenic 
proteins. This was also shown in a cell line that had been commonly employed to study 
neurogenesis and those cells behaved in a similar manner. Furthermore, in PC12 cells, 
Rabex-5 inhibits neurite outgrowth by about 30% and that deletion mutants from the 
Vps9 domain of Rabex-5 were able to rescue neurogenesis. Therefore, it is concluded 
that Rabex-5 contributes to inhibition of adipocyte differentiation and neurite outgrowth 
by promoting degradation of the signaling endosome via: 1) activating Rab5 through the 
Vps9 domain and promoting fusion with early endosome, and 2) ubiquitination of Ras 
through the ZnF domain in the N-terminus and therefore inhibition of the Ras signaling 
cascade (Figure 47).  
Although this dissertation provides better understanding of the interplay between 
receptor tyrosine kinases and activation of Rab5, a few questions remain to be answered. 
Although Rab5 is localized endosomes during fluid phase endocytosis and is activated by 
stimulation with a commonly used fluid phase marker HRP, this activation is much less 
robust, in comparison to what was observed with either EGF or insulin stimulation in this 
dissertation. Furthermore, in mammalian cells overexpression of Rabex-5 induces the 
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formation of enlarged endosomes, as opposed to either Rin1 or RAP6, even though these 
guanine nucleotide exchange factors for Rab5 have been shown to be required in some 
endosome fusion reactions. Therefore, it is plausible that several mechanisms of 
activation of Rab5 are taking place during endocytosis of receptor tyrosine kinases and 
subsequent endosome fusion. Although Rabex-5 was shown to inhibit differentiation of 
fat and neuronal cells through interaction with Rab5, the possibility of its interaction with 
other effectors remains open, since recently it has been shown that Rab22, an effector of 
Rabex-5, actually promotes neurite outgrowth in PC12 cells. Better understanding of the 
interaction of Rab5 guanine nucleotide exchange factors with other members of the Rab5 
subfamily (Rab21, Rab22 and Rab31) may prove to be crucial in understanding 
regulation of various cellular functions that the Rab5 subfamily has been shown to be 
involved in and provide specific targets for pharmaceutical agents to battle debilitating 
diseases. 
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Figure 47. Model for the role of Rabex-5 in differentiation of 3T3-L1 and PC12 cells. 
Model for Rabex-5 dependent activation of Rab5 and ubiquitination of Ras.  A) 
Binding of ligand to a receptor tyrosine kinase leads to autophosphorylation of the 
receptors and activation of Ras and the subsequent Ras signalling cascade (Raf-Mek-Erk) 
which in turn can lead to cellular differentiation, motility, proliferation and survival. On 
the other hand, Ras also interacts with Rin1 (via the SH2 domain) which in turn activates 
Rab5 by catalyzing the conversion of GDP for GTP (via the GEF domain). GTP-bound 
Rab5 then recruits Rabex-5 to the endosome which through its ZnF-MIU domain 
ubiquitinates Ras and therefore attenuates Ras signalling. The early endosome is then 
either destined to be recycled back to the cell surface or to sequentially fuse with late 
endosome and lysosme where the contents of theendosome will be degraded. B) When a 
cell is undergoing differentiation, there is a marked decrease in Rabex-5 expression, 
which leads to a decline in Ras ubiquitination, in turn causing an increase in Ras 
signaling and subsequently the establishment of a signaling endosome (which is void of 
early endosomal markers) stabilizing Ras signaling and therefore allowing differentiation 
to continue. 
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